Document:

Exhibit 4.17

**Confidential portions have been omitted pursuant to a request for confidential treatment 

and have been filed separately with the Securities and Exchange Commission (the “Commission”)**

AMENDED AND RESTATED EXCLUSIVE LEAD SHARING AND DISTRIBUTION AGREEMENT

 

THIS AMENDED AND RESTATED EXCLUSIVE LEAD SHARING AND DISTRIBUTION AGREEMENT (this “Agreement”) is made as of this 29th day of August, 2017 (the “Effective Date”) by and among Mazor Robotics Ltd., with a principal office located at 5 Shacham Street, North Industrial Park, Israel 3088900 ( “Mazor”), Medtronic Navigation, Inc., having a principal office located at 826 Coal Creek Circle, Louisville, CO 80027 (“Medtronic” and, together with Mazor, the “Parties”) and, solely for purposes of Section 7.2 and Section 27, Medtronic plc (“Medtronic Parent”), having a principal office located at 710 Medtronic Parkway, Minneapolis, MN 55432-5604.

 

WHEREAS, Mazor is engaged in developing and manufacturing the Mazor X System, the Renaissance System and the Software Modules; and

 

WHEREAS, the Parties entered into an Exclusive Lead Sharing and Distribution Agreement dated as of May 16, 2016 (the “Original Effective Date”) (as previously amended, the “Original Agreement”), pursuant to which Mazor appointed Medtronic as (i) its co-exclusive lead generation partner for the Mazor X System for spinal applications in the United States, (ii) its non-exclusive lead generation partner for the Mazor X System for spinal applications in Europe, and (iii) its exclusive distributor for the Mazor X System for spinal applications in the Distribution Territory, and Medtronic accepted such appointments; and

 

WHEREAS, the Parties now wish to amend and restate the Original Agreement, all in accordance with the terms and subject to the conditions set forth herein.

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

	1.	
CERTAIN DEFINITIONS

 

1.1.          “Accessories” means the accessory and disposable products for use with the Mazor X System, the current list of which is contained in Exhibit A-5, and which may be updated from time to time by the Parties.

 

1.2.          “Affiliate” means, with respect to any specified Person, any other Person which, but only for so long as such other Person, directly or indirectly, controls, is controlled by, or is under common control with, such specified Person.  The term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, through the ownership of voting securities or other equity interests, and the terms “controlled” and “common control” shall have correlative meanings.

 

1.3.           “Applicable Law” means, with respect to any business or Person, any federal, state, provincial, local, municipal, foreign, international, multinational, supranational or other constitution, statute, law, treaty, ordinance, policy, guidance, rule, administrative interpretation, regulation or other requirement (including common law) applicable to such business or Person or any of their respective Affiliates, properties, assets, officers, directors, managers, employees, consultants or agents (in connection with their activities on behalf of such business or Person or any of its Affiliates), or any charge, order, writ, injunction, directive, judgment, decree, ruling, determination, award or settlement, whether civil, criminal or administrative, of any Governmental Authority having jurisdiction over such business or Person or any of their respective Affiliates, properties, assets, officers, directors, managers, employees, consultants or agents (in connection with their activities on behalf of such business or Person or any of its Affiliates).

 

1.4.           “Business Day” means a day other than a Saturday, a Sunday or a day on which commercial banks are required to be closed in the State of Delaware.

 

1.5.           “Change of Control” means (a) the sale, lease, transfer, exclusive license or other disposition by a Party of all or substantially all of the assets of such Party to a third party; or (b) a merger or consolidation in which (i) a Party is a constituent party or (ii) a subsidiary of a Party is a constituent party and such Party issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation involving a Party or a subsidiary of that Party in which the shares of capital stock of such Party outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1) the surviving or resulting corporation; or (2) if the surviving or resulting corporation is a wholly-owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation.

 

1.6.           “Collaboration Lead” means [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

1.7.           “Demo Installation Date” means the date on which Mazor delivers each of the Demo Units to Medtronic.

 

1.8.           “Disposable Kit Annual Minimum” means, with respect to a Distribution Year, the total number of Mazor X disposable kits that Medtronic is required to purchase from Mazor pursuant to Exhibit A-2.

 

1.9.           “Disposable Kit Cure Amount” means, with respect to a Distribution Year, an amount equal to: [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

2

 

1.10.          “Distribution Period” means the period commencing on the first day of Distribution Year 1 and ending on the final day of Distribution Year 5.

 

1.11.          “Distribution Territory” means [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

1.12.          “Distribution Year” means any of Distribution Year 1, Distribution Year 2, Distribution Year 3, Distribution Year 4 or Distribution Year 5.

 

1.13.          “Distribution Year 1” means the period commencing on September 18, 2017 and ending on April 27, 2018.

 

1.14.          “Distribution Year 1 Minimum Sales Amount” means [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

1.15.          “Distribution Year 2” means the period commencing on April 28, 2018 and ending on April 26, 2019.

 

1.16.          “Distribution Year 2 Minimum Sales Amount” means [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

1.17.          “Distribution Year 3” means the period commencing on April 27, 2019 and ending on April 24, 2020.

 

1.18.          “Distribution Year 3 Minimum Sales Amount” means [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

1.19.          “Distribution Year 4” means the period commencing on April 25, 2020 and ending on April 30, 2021.

 

1.20.          “Distribution Year 4 Minimum Sales Amount” means [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

1.21.          “Distribution Year 5” means the period commencing on May 1, 2021 and ending on April 29, 2022.

 

1.22.          “Distribution Year 5 Minimum Sales Amount” means [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

3

 

1.23.          “Documentation” means any and all operator’s and user’s manuals, training materials, guides, commentary, listings and other materials for use in conjunction with the Products.

 

1.24.          “Europe” means the following countries: the United Kingdom, Ireland, Iceland, Portugal, Spain, France, Belgium, The Netherlands, Luxembourg, Germany, Switzerland, Austria, Italy, Malta, Monaco, Denmark, Norway, Sweden, Finland, Estonia, Latvia, Lithuania, Poland, Czech Republic, Slovak Republic, Hungary, Croatia, Bosnia & Herzegovina, Serbia, Kosovo, FYRO Macedonia, Albania, Greece, Israel, Bulgaria, Romania, Moldova, Ukraine and Belarus.

 

1.25.          “Exclusive Lead Generation Territory” means the United States of America.

 

1.26.          “Exclusive Territory” means any Territory in which Mazor grants Medtronic exclusive rights with respect to the Mazor X System during the Term, but excluding any Territory in which Medtronic’s rights are co-exclusive.

 

1.27.          “Governmental Authority” means any federal, state, local, foreign or supranational governmental authority, quasi-governmental authority, instrumentality, court, government or self-regulatory organization, commission, tribunal or organization or any regulatory, administrative or other agency, or any political or other subdivision, department or branch of any of the foregoing.

 

1.28.          “Hardware Customizations” means any customizations made by Mazor to Mazor hardware and/or tools for use with implants for the Mazor X System in order to enable the Software Customizations and use thereof with the Medtronic spinal instruments and implants, but expressly excluding Medtronic Background IP and/or Medtronic Development IP.

 

1.29.          “Intellectual Property” means all rights to patents, patent applications, software, copyrights, trademarks, trade secrets, know-how, concepts, designs, specifications, techniques, formulas, inventions, trade names, labels, trade dress, literature, programs, methodologies, advertising material or other documents, materials or information relating to the products or the business operations of a Party to this Agreement or owned by such Party or any of its affiliated persons or entities.

 

1.30.          “Joint Invention” means any invention that is made or developed jointly by inventors who are employed by, or otherwise who have an obligation to assign their rights to any such invention to Mazor and by inventors who are employed by, or otherwise who have an obligation to assign their rights to such invention to Medtronic, whether or not conceived in conjunction with employees or agents of a third party.

 

1.31.         “Lead Generation Cure Amount” means [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] Qualified Leads.

 

4

1.32.          “Lead Generation Cure Payment Amount” means an amount equal to (a) [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION], times (b) the number of Qualified Leads by which the Lead Generation Milestone Amount exceeds the number of Qualified Leads generated by Medtronic during the Lead Generation Period.

 

1.33.          “Lead Generation Milestone Amount” means [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] Qualified Leads.

 

1.34.          “Lead Generation Adjustment Amount” means that number of Mazor X Systems equal to (i) [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION], minus (ii) the actual number of Qualified Leads that are converted into sales during the Lead Generation Period.

 

1.35.          “Lead Generation Period” means the period commencing on the Demo Installation Date and ending as of the beginning of Distribution Year 1.

 

1.36.          “Mazor Background IP” means any invention(s) in existence and owned by, or licensed to, Mazor prior to the Original Effective Date.

 

1.37.          “Mazor Development IP” means any invention(s) conceived or reduced to practice solely by Mazor’s employees, consultants or agents and arising from work performed by such employees, consultants or agents under, or in connection with, this Agreement.

 

1.38.          “Mazor X Navigation and Guidewireless Program” means the research and development program embodied in Statement of Work #1 in Exhibit E attached to and made a part of this Agreement, which the parties have entered into as of the Effective Date.

 

1.39.          “Mazor X System” means the Renaissance X surgical guidance system (also known as the Mazor X system) as used for spinal applications as set forth in Exhibit A-3 attached to and made a part of this Agreement, and shall include all improvements, updates, upgrades and enhancements thereto, and future generations thereof.

 

1.40.          “Medtronic Background IP” means as any invention(s) in existence and owned by, or licensed to, Medtronic prior to the Original Effective Date and including without limitation (i) any CAD models relating to Medtronic spine instruments or implants or documentation provided by Medtronic for the development of Software Customizations hereunder, or (ii) the Navigation Software Module provided by Medtronic to Mazor pursuant to or in connection with Mazor X Navigation and Guidewireless Program.

 

1.41.          “Medtronic Development IP” means any invention(s) conceived or reduced to practice solely by Medtronic’s employees, consultants or agents and arising from work performed by such employees, consultants or agents under, or in connection with, this Agreement.

5

 

1.42.          “Medtronic Sales Representatives” means members of Medtronic’s sales force.

 

1.43.          “Medtronic Spinal Construct” means any spinal fixation system consisting of pedicle screws and rods that is designed, manufactured, sold or commercialized by Medtronic or any of its Affiliates.

 

1.44.          “Minimum Sales Amount” means, with respect to a Distribution Year, the applicable Distribution Year Minimum Sales Amount.

 

1.45.          “MSA Condition” means any of the following [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

1.46.         “Non-Exclusive Lead Generation Territory” means [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

1.47.          “Non-Exclusive Territory” means any Territory in which Mazor grants Medtronic rights with respect to the Products during the Term that are not exclusive rights.

 

1.48.          “Net Sales” means the aggregate amount of gross revenue received as a result of the sale of any Products to third parties during the relevant measurement period (in each case, determined in accordance with GAAP), less any taxes, tariff duties, discounts, returns, marketing grants, or rebates actually given or credited, as determined without duplication, to the extent allocable to such sales of Products.

 

1.49.          “One-Surgeon Lead” means a sales account with respect to which [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

1.50.          “Original Agreement” is defined in the Recitals.

 

1.51.          “Original Effective Date” is defined in the Recitals.

 

1.52.          “Person” means any natural person or any corporation, partnership, limited liability company, business association, joint venture or other entity.

 

1.53.          “Products” means, collectively, the Mazor X System for spinal applications, the Accessories for spinal applications and the Software Modules for spinal applications, and shall include all improvements, updates, upgrades, enhancements and future generations, but excluding any Software Customizations.

 

1.54.          “Qualified Lead” means [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

6

		(a)	
[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

		(b)	
[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

		(c)	
[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

		(d)	
[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

1.55.          “Regulatory Approval” means a product-specific approval from a Governmental Authority necessary for the research, development, manufacture, distribution, pricing, reimbursement, marketing or sale of any of the Products in any Territory.

 

1.56.          “Restricted Period” means [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

1.57.          “Renaissance System” means the Renaissance surgical guidance system (also known as the Mazor system), and shall include all improvements, updates, upgrades and enhancements thereto, and future generations thereof.

 

1.58.          “Sales Cure Payment Amount” means, with respect to a Distribution Year, an amount equal to (a)(i)(A) the Minimum Sales Amount with respect to such Distribution Year, minus (B) the number of Mazor X Systems sold by Medtronic in such Distribution Year (the sum of (a)(i)(A), minus (B), the “Shortfall Amount”), times (ii) [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION], which amount shall be payable within ten (10) Business Days after the end of such Distribution Year if Medtronic elects to pay the Sales Cure Payment Amount applicable to such Distribution Year, plus (b)(i) only if Medtronic does not exceed the Minimum Sales Amount applicable to the subsequent Distribution Year, an amount equal to (A) the Shortfall Amount, times, (B) [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] or (ii) if Medtronic does exceed the Minimum Sales Amount applicable to such subsequent Distribution Year, an amount equal to [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION], which amount shall be payable within ten (10) Business Days after the end of such subsequent Distribution Year.

 

7

1.59.          “Software Customizations” means any software or software code developed under this Agreement with the specific applicability to deploy Software Modules on the StealthStation and/or to integrate Medtronic spine instruments and/or implants with the Mazor X System and/or Software Modules as permitted under this Agreement but expressly excluding Medtronic Background IP and/or Medtronic Development IP.

 

1.60.          “Software Modules” means the software modules associated with the Mazor X System as used for spinal applications and shall include all improvements, Software Updates, upgrades and enhancements thereto, and future generations thereof.

 

1.61.          “Software Updates” means updates to the Software Modules that are required for safety or security-related reasons, including bug fixes, patches, and corrections. Software Updates does not include upgrades, enhancements, new versions or releases that add additional functionality or require additional functional hardware to run the update.

 

1.62.          “StealthStation” means Medtronic’s pre-operative, intra-operative, or post-operative computer assisted, image-guided surgery system used to facilitate automated localization of instruments for use in a surgical or interventional procedure.

 

1.63.          “Term” is defined in Section 17.

 

1.64.          “Territory” means, as the context requires, either the Distribution Territory, or the Exclusive Lead Generation Territory together with the Non-Exclusive Lead Generation Territory.

 

1.65.          “Training Materials” means all written training materials and related written guidelines provided by Mazor to Medtronic relating to the Products, including, without limitation, all Promotional Materials.

 

1.66.          “Two-Surgeon Lead” means a sales account with respect to which [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

1.67.           “Upgrade” means the exchange by a customer of a Renaissance System for a Mazor X System.

 

1.68.          “Upgrade Fee” means the fee payable by a customer in exchange with an Upgrade.

 

1.69.          “U.S. Lead Generation Period” means the period commencing on the Demo Installation Date and ending on the 12-month anniversary of the Demo Installation Date.

 

	2.	
 APPOINTMENT OF LEAD GENERATOR AND DISTRIBUTOR

 

2.1.            Mazor hereby grants to Medtronic, commencing on the Original Effective Date, the co-exclusive right (with Mazor) to generate sales leads with respect to, and otherwise advertise, promote and market the Mazor X System for spinal applications within the Exclusive Lead Generation Territory during the Lead Generation Period, which appointment Medtronic hereby accepts.

 

8

2.2.            Mazor hereby grants to Medtronic, commencing on the Original Effective Date, the non-exclusive right to generate sales leads with respect to, and otherwise advertise, promote and market the Mazor X System for spinal applications within the Non-Exclusive Lead Generation Territory during the Lead Generation Period, which appointment Medtronic hereby accepts.

 

2.3.            Mazor hereby grants to Medtronic, effective upon the commencement of the Distribution Period, the exclusive right, within the Distribution Territory, to distribute, sell, advertise, promote, market and otherwise commercialize the Mazor X System, the Accessories and the Software Modules, in each case for spinal applications, which appointment Medtronic hereby accepts.

 

2.4.            During the Term, Mazor shall not grant to any other Person within any Exclusive Territory the right or license, either directly or indirectly, to distribute, sell, advertise, promote, market or otherwise commercialize, the Mazor X System, the Accessories and Software Modules, in each case for spinal applications  Without limiting the foregoing, during the Term, Mazor shall not enter into any type of agreement or arrangement for the private-labeling of the Mazor X System, the Accessories and Software Modules, in each case for spinal applications.

 

2.5.            Medtronic may appoint sub-dealers or sub-distributors and may advertise, promote, market, distribute, sell and otherwise commercialize the Products through such sub-dealers and sub-distributors within any Territory to the extent Medtronic has rights in any such Territory and on terms consistent with the terms of this Agreement.  Any contract or similar agreement entered into between Medtronic and a sub-dealer or sub-distributor shall include: (a) confidentiality and use restrictions that are no less restrictive than those set forth in this Agreement; and (b) intellectual property ownership provisions consistent with those set forth in this Agreement. Any breach by a sub-dealer or sub-distributor of its obligations shall be deemed to be a breach by Medtronic.

 

2.6.            Notwithstanding anything to the contrary in this Section 2, nothing in this Agreement shall limit or restrict Mazor from: (a) performing all installations and warranty repairs for new systems, preventative maintenance, repairs and Software Updates or upgrades for the Products; or (b) modifying, manufacturing, distributing, selling, advertising, promoting, marketing or otherwise commercializing (i) the Mazor X System, the Accessories or Software Modules in each case for non-spinal applications or (ii) the Renaissance System in any Territory for any purposes, provided however that in the case of (b)(ii), [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

9

 

	3.	
MARKETING AND PROMOTION

 

3.1.            Medtronic Marketing Obligations.

 

(a)         Marketing Activities.  Medtronic will (i) advertise and promote and (ii) use commercially reasonable efforts to sell and otherwise create a demand for the Products in the Territory (“Marketing Activities”).  Mazor acknowledges that Medtronic does not guarantee that the Marketing Activities will successfully create demand for the Products or that the minimums set forth in Section 4.1 and Section 8.1 will be obtained as a result of Medtronic’s efforts.  The Marketing Activities shall include:

 

(i)           presenting and demonstrating the Products at least at the following industry conferences and trade shows: American Academy of Neurological Surgeons, Congress of Neurological Surgeons, North American Spine Society, and Scoliosis Research Society;

 

(ii)          showcasing, demonstrating and promoting the Products in product marketing suites located in Medtronic facilities in Memphis, TN, Louisville, CO and other facilities as deemed appropriate by Medtronic;

 

(iii)         educating Medtronic’s internal staff on the Products;

 

(iv)         developing and executing internal and external marketing campaigns for the Products;

 

(v)          producing and distributing brochures and testimonials suitable to effectively market the Products to surgeons and hospitals;

 

(vi)         promoting the Products through customary media channels, including Medtronic’s social media accounts and website;

 

(vii)        targeting potential customers; and

 

(viii)       committing a qualified team of employees to be responsible for overseeing and executing the marketing of the Products.

 

(b)          Sales and Marketing Plan.  Exhibit B sets forth Medtronic’s initial sales and marketing plan with respect to the Products (the “Medtronic Sales and Marketing Plan”).  Medtronic will (i) implement the Medtronic Sales and Marketing Plan promptly following the Original Effective Date, and throughout the Term in accordance with clause (ii), and (ii) cooperate with Mazor to update the Medtronic Sales and Marketing Plan throughout the Term taking into account Mazor’s feedback.  The Medtronic Sales and Medtronic Sales and Marketing Plan will include detailed descriptions of how Medtronic will meet its obligation to provide the Marketing Activities, as well as details about Medtronic’s sales team for the Products.  The Steering Committee will review the status of Medtronic’s marketing efforts under the Medtronic Sales and Marketing Plan and will discuss updates and deviations therefrom.  At intervals reasonably requested by Mazor, Medtronic shall provide Mazor with (a) its potential customer pipeline, (b) all information relating to the sales of the Products in the Territory, and (c) feedback on the Products received from customers and potential customers.

 

10

(c)         Sales Incentive Plan.  [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

(d)         Promotional Materials.  Medtronic will use, and will only permit the Medtronic Sales Representatives to use, Promotional Materials approved by Mazor, and then only in accordance with this Agreement and the Training Materials.  To assist in the continuing improvement of the Promotional Materials, Medtronic will provide feedback on the Promotional Materials to the Steering Committee.  Medtronic will be responsible, at its sole cost, for producing, printing, and distributing the Promotional Materials in accordance with the Medtronic Sales and Marketing Plan.

 

(e)          Promotional Collaboration.  As further contemplated in Section 5 hereof, the Steering Committee will collaborate with respect to the Marketing Activities.

 

(f)          Compliance with Laws.  Medtronic will comply with all Applicable Laws relating to the execution of its obligations under this Agreement including, without limitation, with respect to the Marketing Activities.

 

  (g)         Liability Cap.  Notwithstanding anything herein to the contrary, Medtronic may only be liable to Mazor for damages (which damages shall exclude, for the avoidance of doubt, incidental, consequential, special, general, proximate, indirect, punitive or exemplary damages, but may include (i) lost revenue and lost profits regardless of whether such are deemed consequential, indirect or other damages, and (ii) reasonable attorneys’ and litigation fees and expenses) resulting from any actual or claimed breach of Sections 3.1, 8.1 or 18.2(a)  to the extent that such damages have been awarded to Mazor pursuant to a final, non-appealable order of any court of competent jurisdiction or a final and binding arbitration order (“Distribution Damages”) and the maximum aggregate liability of Medtronic for all claims made by Mazor for any actual or claimed breaches of Sections 3.1, 8.1 or 18.2(a) relating to or arising from a given Distribution Year will not exceed an amount equal to $2,000,000 (the “Distribution Liability Cap”); provided, that reasonable attorneys’ and litigation fees and expenses actually incurred by Mazor in connection with any successful attempt by Mazor to recover Distribution Damages (including any of those awarded pursuant to Section 30.2) shall not count toward the Distribution Liability Cap.  Notwithstanding the foregoing, the Distribution Liability Cap shall not apply to Medtronic’s indemnification obligations pursuant to Section 25 or in connection with an intentional breach by Medtronic of Section 3.1, 8.1 or 18.2(a).

 

11

3.2.            Mazor Support.  Mazor will provide the following promotional support services:

 

(a)         Marketing Support Matters.  Without limiting Section 3.1, Mazor will be responsible for, at its own cost and expense, during the Lead Generation Period, the development of all promotional, non-promotional, training and educational materials relating to the Products (the “Promotional Materials”).  Mazor will also be responsible for:

 

(i)           Mazor’s and the Products’ websites;

 

(ii)          patient and market research and support;

 

(iii)         therapy awareness programs;

 

(iv)         ethics and compliance (but only with respect to its employees and materials);

 

(v)          adverse events and reporting;

 

(vi)         call centers/customer service and complaint handling;

 

(vii)        Product pricing; and

 

(viii)       Clinical support plans.

 

The Promotional Materials and other support shall be provided to Medtronic in the English language.  Medtronic shall be responsible for translating the materials into any other languages necessary to distribute them in the Territories.  Mazor will be responsible for assuring that no Promotional Materials violate any Applicable Laws at the time of the provision thereof to Medtronic and/or its Affiliates, and will indemnify Medtronic against any losses arising from Medtronic’s use or dissemination of the Promotional Materials in accordance with the Promotional Training and Promotional Materials as provided in Section 25 below.

 

(b)         Compliance with Laws.  Mazor will comply with all Applicable Laws relating to the execution of its obligations under this Agreement including, without limitation, with respect to the manufacture and supply of the Products, Promotional Training and Promotional Materials.

 

3.3.          Responsibility for Translations.

 

(a)         Mazor Responsibilities.  Mazor will be responsible for (i) obtaining the translation of the user documentation for the Products and of the software interface for the Mazor X System into all languages as requested by Medtronic (the costs of which in respect of the English, French, Italian, German and Spanish languages will be borne by Mazor), and (ii) implementing all languages into the user documentation for the Products and into the software interface for the Mazor X System as requested by Medtronic (the costs of Mazor employees to implement the languages of which will be borne by Mazor).

 

(b)         Medtronic Responsibilities.  Medtronic will bear the costs for Mazor to obtain the translation of the user documentation for the Products and of the software user interface for the Mazor X System into all languages other than English, French, Italian, German and Spanish. Including the responsibility for the translation validation.

 

12

	4.	
LEAD GENERATION

 

4.1.           Generation of Qualified Leads.  During the U.S. Lead Generation Period, Medtronic will generate and provide to Mazor Two-Surgeon Leads and One-Surgeon Leads, and work together with Mazor on Collaboration Leads, in accordance with Applicable Laws and the terms and conditions of this Agreement and the Medtronic Sales and Marketing Plan (“Lead Generation Services”).  Mazor acknowledges that Medtronic does not guarantee the success of the Lead Generation Services or that the Lead Generation Milestone Amount will be obtained as a result of Medtronic’s efforts.  Medtronic will provide Mazor with a quarterly report detailing the Lead Generation Services.

 

4.2.           Support Services.  Except as expressly stated otherwise herein, Medtronic will provide all requisite management, oversight, facilities, equipment and administrative support necessary for the Medtronic Sales Representatives to perform the Lead Generation Services or Marketing Activities hereunder, including the following:

 

(a)         Management. Medtronic will be solely responsible for the management and discharge of, and shall manage and discharge, all employer obligations in connection with its employees who perform the Lead Generation Services or Marketing Activities (including all members of the Medtronic Sales Representatives, including all human resource issues, the fulfillment of employer obligations required by Applicable Laws, the payment of compensation, the remittance to the proper Governmental Authorities of all employee withholdings and employer contributions required by Applicable Laws or other requirements, the administration of health and benefits plans and other employee benefit plans in compliance with Applicable Laws, the oversight and management of any work performance issues, and all other day to day management and employment issues in connection with its employees who perform the Lead Generation Services and Marketing Activities.

 

(b)         Discipline.  Medtronic has sole authority to remove personnel from the Medtronic Sales Representatives involved in the provision of Lead Generation Services and Marketing Activities under this Agreement, and to comply with Medtronic policy regarding the treatment of employees.  Notwithstanding the foregoing, Medtronic will reasonably investigate any reports made by Mazor of any non-compliance with this Agreement by a Medtronic Sales Representative and Medtronic will apply such counseling, discipline, removal or termination of such individual as may be warranted in Medtronic’s reasonable judgment.

 

4.3.            Retained Rights.  Except as contemplated in this Agreement, during the Lead Generation Period within the Exclusive Lead Generation Territory, Mazor will retain all rights and responsibilities with respect to the Products including, without limitation, the following: pricing (including with respect to trade, quantity or other discounts) and terms of sale; research and development; manufacturing, labeling, packaging and distribution (including order processing and fulfillment, returns handling, and credits); all sales matters including order fulfillment; regulatory affairs; safety of the design of the Products; transparency obligations of Mazor under Applicable Laws (e.g., “Sunshine” Act); product policies and procedures; all intellectual property matters relating to the Products; all litigation and claims relating to the Products.  In addition to any assistance that Medtronic is required to provide to Mazor to meet its obligations under this Agreement, Medtronic will, at Mazor’s cost and expense, provide reasonable assistance to Mazor in support of each of these areas upon reasonable written request.

 

13

4.4.            Lead Generation Fees and Payment Terms.

 

  (a)         Lead Generation Fees.  With respect to each sale of a Mazor X System during the Lead Generation Period resulting from a Two-Surgeon Lead, a One-Surgeon Lead or a Collaboration Lead, Mazor will pay to Medtronic a fee (a “Lead Generation Fee”) equal to the greater of (i) [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] and (ii) an amount equal to [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] of the Net Sales received by such sale.  Once Mazor has paid Medtronic [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] Lead Generation Fees, for each additional sale of a Mazor X System during the Lead Generation Period resulting from a Two-Surgeon Lead, a One-Surgeon Lead or a Collaboration Lead, Mazor will pay to Medtronic a fee equal to the greater of (i) [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] and (ii) an amount equal to [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] of the Net Sales received by such sale.  No Lead Generation Fee shall be payable with respect to any Demo Units or any Initial Placed Unit even if such unit is sold to a customer.

 

[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

  Notwithstanding the above, Lead Generation Fees with respect to Upgrades will be [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] of the actual Net Sales price.

 

(b)         Reports.  Mazor will prepare a report each month during the Lead Generation Period (a “Monthly Lead Generation Report”) detailing, with respect to such month (i) the date of each sale of a Mazor X System, (ii) each customer to whom a Mazor X System was sold, (iii) the Net Sales price of each Mazor X System sold and (iv) the aggregate Net Sales resulting from Qualified Leads during the applicable month.  Each Monthly Lead Generation Report will be based on data reported by Mazor or a third party data source and will be delivered to Medtronic within fifteen (15) days after the end of each month.

 

14

(c)         Payment.  Mazor will pay Medtronic the Lead Generation Fee applicable to Net Sales included in a Monthly Lead Generation Report no later than thirty (30) days following the actual collection of the gross revenue received as a result of the sale of the Products to which such Net Sales relate, but in any event no later than one hundred twenty (120) days following the installation of such Products.

 

(d)         Net Sales. Each of Mazor and Medtronic will maintain complete and accurate records of and supporting documentation relating to the Lead Generation Services.

 

4.5.            Mazor’s sole remedy for any actual or claimed breach by Medtronic of this Section 4 shall be termination in accordance with Sections 18.3 and 18.6, as applicable.

 

	5.	
GOVERNANCE.

 

5.1.           Steering Committee.  Medtronic and Mazor will establish a Steering Committee (the “Steering Committee”) to oversee all matters relating to this Agreement, including the performance of the Marketing Activities and Lead Generation Services and to discuss and make decisions regarding strategic and tactical matters and opportunities during the Term.  The Steering Committee will be composed of an equal number of representatives of Medtronic and Mazor.  Advice delivered by a Party through the Steering Committee will be advisory only and not binding on the other Party absent the agreement of both Parties hereto.

 

(a)         Meetings.  Throughout the Term, the Steering Committee will meet monthly by video or telephone conference, or as otherwise agreed by the Steering Committee.  The Steering Committee will conduct quarterly business review meetings  At each such quarterly meeting, Medtronic will present, at a minimum, its distribution performance and activities over the last quarter, and plans for the next 12 months.  Other issues relating to or arising out of this Agreement may also be discussed.  If any meeting is held in person, each of Medtronic and Mazor will be responsible for its own expenses relating to such meeting.  As appropriate, other employee representatives of the Parties may attend Steering Committee meetings as non-voting participants, but no third party personnel may attend unless otherwise agreed by the Parties.  Each of Medtronic and Mazor may also call for special meetings of the Steering Committee as reasonably required to resolve particular matters identified by such Party, subject to the availability of the other members of the Steering Committee.

 

(b)         Decision-Making.  The Steering Committee will make decisions by consensus.  Any deadlock of Steering Committee members will be escalated to the Executive Sponsors for resolution.

 

(c)         No Authority to Modify Agreement.  Notwithstanding anything in this Agreement to the contrary, the Steering Committee will have no authority to amend or waive compliance with any of the provisions of this Agreement, or to approve actions of the Parties that are in violation of or inconsistent with this Agreement.  Any such amendments, waivers or actions will only be effected and implemented in accordance with Section 30.9 of this Agreement.

 

15

(d)         Establishment of Subcommittees.  The Steering Committee shall have the right to establish subcommittees or working teams with respect to issues within its area of responsibility as it sees fit, including at Territory and regional levels.

 

5.2.            Executive Sponsors.  Promptly after the Original Effective Date, each of Medtronic and Mazor will appoint a single person (each, an “Executive Sponsor”) who will oversee the activities of the Steering Committee, attempt to resolve issues referred to them by the Steering Committee, and perform such other functions as they may determine from time to time.  Issues which cannot be resolved by the Executive Sponsors will be resolved in accordance with Section 30.2 of this Agreement.  The Executive Sponsors shall meet (which may be in person or by videoconference or by telephone) on an as-needed basis for these purposes as agreed by the Executive Sponsors at such times and places as they shall determine.  Each Party shall have one (1) Executive Sponsor. The provisions of Section 5.1 regarding the Steering Committee shall also apply with the same force and effect with respect to the Executive Sponsors.

 

	6.	
INITIAL SYSTEM PURCHASE

 

[RESERVED, it being agreed that the terms “Initial System Purchase”, “Demo Units” and “Initial Placed Units” will be defined by reference to the Original Agreement.]

 

	7.	
EMPLOYEE MATTERS

 

7.1.            [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

7.2.            Except as required of Medtronic by Section 7.1, during the Term, and for a period of one (1) year thereafter, each Party and Medtronic Parent shall not solicit for employment or the provision of services, or hire for employment or the provision of services, personnel of the other Party or its Affiliates. The foregoing restriction shall not restrict the right of either Party or Medtronic Parent to solicit or recruit generally in the media, and shall not prohibit either Party or Medtronic Parent from hiring an employee of the other Party who answers any advertisement or who otherwise voluntarily applies for employment or contacts the other Party or Medtronic Parent, without having been initially personally contacted, solicited or recruited by the hiring Party or Medtronic Parent.

 

	8.	
DISTRIBUTION

 

8.1.            During each Distribution Year, Medtronic shall use commercially reasonable efforts to sell the number of Mazor X Systems that is equal to or greater than the Minimum Sales Amount applicable to such Distribution Year.  Mazor acknowledges that Medtronic does not guarantee that the Marketing Activities or its other services under this Agreement will result in sales of the Products that are equal to or in excess of the Minimum Sales Amounts as contemplated by this Section 8.1.

 

8.2.            Medtronic’s orders for Products from Mazor shall be made by written purchase order. Mazor shall ship the ordered Products in accordance with the schedule and shipping instructions specified by Medtronic.  Upon shipment, Mazor shall promptly invoice Medtronic.

 

16

8.3.            Mazor shall package and label Products in accordance with mutually agreed specifications and good commercial practices for capital and, as applicable, sterile, medical devices, and in a manner sufficient to withstand the rigors of transportation. Packaging shall be appropriately validated in accordance with industry standards.

 

8.4.            Prices for the Products ordered by Medtronic from Mazor shall be at the prices set forth in Exhibit A-1 to this Agreement, subject to adjustment pursuant to Section 21.2 hereof.  Unless otherwise agreed to in writing, prices shall be deemed to include packing and crating expenses, but exclude (except as otherwise set forth in Section 8.5) shipping and taxes (including, without limitation, all excise, tariffs, import duties, and VAT).  Except with respect to the Initial System Purchase, Mazor agrees to ship only those quantities specified in purchase orders and Medtronic may return Products in excess of specified quantities to Mazor at Mazor’s risk and expense.

 

8.5.            For Mazor X systems shipped to the U.S., shipping will be DAP (Incoterms 2010) to a Medtronic distribution center of Medtronic’s choosing.  Mazor shall be responsible for export clearance.  Medtronic shall be the importer of record and shall be responsible for import customs clearance and import taxes.  Title and transfer of the product will pass upon delivery at the Medtronic distribution center.  For Mazor X systems shipped outside of U.S., and for all Accessories (regardless of shipping destination), shipping will be FOB from Israel.  Mazor shall be responsible for export clearance.  Medtronic shall be the importer of record and shall be responsible for import customs clearance and import taxes.  Title and transfer of the product will pass upon shipping from Israel.

 

8.6.            All amounts due to Mazor shall be payable in United States Dollars net forty-five (45) days from invoice date.

 

8.7.            Forecasts.  Prior to the last Business Day in each calendar quarter, Medtronic shall deliver to Mazor a monthly forecast of Products to be purchased during the subsequent nine (9)-month period, together with the requested quantities and the requested delivery date(s) for each of the nine (9) months thereof.  Each monthly forecast provided will constitute a non-binding forecast of Medtronic’s projected requirements for the Products.

 

8.8.            Inventory Purchases.  Based on the Forecasts, Mazor shall purchase, on a rolling basis, components and raw materials as necessary to manufacture Medtronic’s forecasted quantity of Products based on any applicable lead times and efficient order quantities (“Inventory”).

 

8.9.            Purchase Orders.  Mazor will use its best efforts to fulfill orders for Products within ninety (90) days of placement of the relevant purchase order.

 

8.10.          [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

8.11.          Unutilized Distribution Territory.  At any time during the Distribution Period, Mazor may request that Medtronic relinquish the exclusive distribution rights it may have pursuant to this agreement with respect to a Territory, or any portion thereof, in which Medtronic is not actively selling Products at such time, which request may not be unreasonably rejected by Medtronic.

 

8.12.          Exclusive Territories.  In the event that any Product is sold or distributed by Mazor or any other party (other than Medtronic or its representative) in an Exclusive Territory, except as otherwise permitted by this Agreement, Medtronic will have the right to deem such sale as a sale made by Medtronic for which Mazor shall pay Medtronic the sales revenue received by Mazor less the transfer price defined in Exhibit A on such sale and which sale shall count as a sale by Medtronic for purposes of this Agreement, including for purposes of Sections 17 and 18.4.

17

 

	9.	
TRAINING

 

9.1.            During Lead Generation Period.

 

  (a)        Mazor will provide training (“Training”) to approximately three hundred (300) to four hundred (400) surgeons and fifty (50) to one hundred and fifty (150) Medtronic Sales Representatives and clinical personnel at its United States bioskills cadaver lab during the Lead Generation Period and will develop the capacity to accommodate such number of surgeons and Medtronic Sales Representatives and clinical personnel, and Mazor will be responsible for the logistics (e.g., arranging air travel, booking accommodations, making transfers, and operating the bioskills labs, surgery observations and surgery videos) relating to such Training sessions; provided, however, that Medtronic will be responsible for arranging air travel and booking accommodations for the Medtronic Sales Representatives and clinical personnel.  Each of Medtronic and Mazor will pay one half (1/2) of all of the training costs set forth on Exhibit C hereto relating to surgeon Training. Medtronic shall pay the full amount of the training costs set forth on Exhibit C hereto related to Training for Medtronic Sales Representatives and clinical personnel.

 

  (b)         Mazor will facilitate a European bioskills cadaver lab available to Medtronic Sales Representatives and customers up to six (6) times during the Lead Generation Period.  Medtronic will reimburse Mazor for all reasonable, documented costs and expenses associated with such Training sessions.

 

  (c)         Medtronic will provide up to two (2) training sessions, each of which will accommodate up to forty (40) people, to Mazor’s sales and clinical teams on the use of Medtronic Spinal Constructs as determined by the Steering Committee.

 

9.2.            During Distribution Period.  Following the commencement of the Distribution Period, Medtronic will be responsible for surgeon training.

 

9.3.            Instruments and Implants.  Medtronic will provide a reasonable quantity and quality of the instruments and implants required to be utilized in the Training sessions contemplated by Section 9.1 at no cost to Mazor.

 

18

	10.	
CASE COVERAGE

 

10.1.          Lead Generation Period.  During the Lead Generation Period, Mazor will be responsible for case coverage with respect to users of the Mazor X System in the Exclusive Lead Generation Territory and Medtronic will be responsible for case coverage with respect to users of the Mazor X System in the Non-Exclusive Lead Generation Territory.

 

10.2.          Transition Period.  Notwithstanding Sections 10.3 and 12 of this Agreement, during a transition period to be agreed by the Parties but expected to be between [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] of the beginning of the Distribution Period (the “Transition Period”), Mazor will be responsible for case coverage with respect to users of the Mazor X System.  Mazor will utilize clinical sales representatives (“CSRs”) trained on the Mazor X to cover cases, including those CSRs to whom Medtronic makes on offer of employment but whose start date coincides with the end of the Transition Period.  In consideration of the foregoing, Medtronic agrees to pay Mazor a fee of [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] per week of the Transition Period, billable monthly, and payable net 45 days.  Also during the Transition Period, but not thereafter, Mazor will be responsible for selling Accessories to Mazor X customers; it being agreed that such sales of Accessories during the Transition Period will be on terms and at sales levels reasonably consistent with Mazor’s prior ordering practices relating to Accessories, based on reasonable efforts.

 

10.3.          Distribution Period.  During the Distribution Period and following the Transition Period, Medtronic will be responsible, at no charge to Mazor, for case coverage in the Distribution Territory with respect to users of the Mazor X System in connection with any spinal procedures, whether or not a Medtronic Spinal Construct is used, including, for clarity, with respect to Mazor X Systems sold prior to commencement of the Distribution Period.

 

	11.	
IMPLANT FEE

 

Throughout the Term, Medtronic agrees to pay Mazor implant fees (“Implant Fees”) with respect to cases in which the Mazor X System is utilized and Medtronic Spinal Constructs are implanted, as specified in Exhibit A-4; provided, however, that no Implant Fee shall be payable with respect to any case utilizing an Initial Placed Unit; provided, further, that during any period throughout the Term during which at least five (5) Mazor X Systems have been on backorder for at least two (2) months, Medtronic will have no obligation to pay Implant Fees with respect to cases in which Medtronic Spinal Constructs are used until such time as there shall be no Mazor X Systems on backorder.

19

 

In addition, Medtronic shall pay Implant Fees with respect to cases in which the Mazor Renaissance System is utilized and Medtronic Spinal Constructs are implanted, as follows:  (a) [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] for each single level case in which the Mazor Renaissance System is utilized and Medtronic Spinal Constructs are implanted, (b) [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] for each two level case or three level case in which the Mazor Renaissance System is utilized and Medtronic Spinal Constructs are implanted and (c) [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] for each four level case and above in which the Mazor Renaissance System is utilized and Medtronic Spinal Constructs are implanted; subject to the following:

			
The Implant Fee for cases in which the Mazor Renaissance System is utilized shall only apply to cases performed that constitute incremental implant revenue for any particular surgeon.  [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

			
The Implant Fee for the surgeon in which the Mazor Renaissance System is utilized shall only be applicable for a period of twenty-four (24) months from the date the Incremental Implant Revenue Threshold is calculated for the surgeon.

Medtronic will be responsible for sending all clinical case reports to Mazor.  At the end of each month, Mazor will provide Medtronic with an Implant Fee report based on the clinical case reports.  Medtronic will have three (3) business days to review and validate the report, after which Mazor shall promptly invoice Medtronic for Implant Fees.  Medtronic will pay Mazor each invoice within forty-five (45) days from invoice date.

 

With respect to Renaissance Implants Fees, Mazor will provide a summary report to Medtronic on a quarterly basis, regarding RNS cases where MDT implants were used.

 

	12.	
MAZOR X DISPOSABLE KITS

 

For each Mazor X System sold by Medtronic hereunder, Medtronic shall place purchase orders for Mazor X disposable kits equal to or greater than the annual minimum quota requirements for Mazor X disposables kits set forth in Exhibit A-2. In the event that Medtronic does not purchase a number of Mazor X disposable kits equal to or greater than the Disposable Kit Annual Minimum in any Distribution Year, then Mazor shall invoice Medtronic for the Disposable Kit Cure Amount and Medtronic shall pay the Disposable Kit Cure Amount within forty-five (45) days of the date of the invoice.

 

	13.	
PAYMENT TERMS

 

13.1.          No Right of Set Off.  Each Party expressly waives any right to set-off against any amounts due to it under this Agreement.

 

13.2.          Late Fees.  In the event that either Party fails to make a payment of any amounts when due in accordance with this Agreement, such Party will pay a late fee, calculated at the amount of the late payment multiplied by the lesser of one percent (1%) per month or the maximum amount permissible under Applicable Law, for each day between day such amounts were due and the day payment is made.

 

20

13.3.          Accounting.  Each Party will maintain complete and accurate records of and supporting documentation relating to any amounts owed to such Party under this Agreement.

 

13.4.          Account Details.  Unless otherwise notified in writing by a Party at least fifteen (15) calendar days before any payment required hereunder, the payment method for the settlement of all payments hereunder will be by wire transfer of immediately available funds to the following bank accounts, and each Party will send the other Party details of any wire transfer at least five (5) days prior to the execution of such wire transfer:

 

  Payments to Medtronic:

[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

  Payments to Mazor:

[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

	14.	
SERVICE

 

14.1.          By Mazor.

 

(a)         For all Mazor X Systems, Mazor shall provide the full one (1) year product warranty as described in Section 15.1 below; after such warranty period, service agreements shall be made available to customers. Mazor shall be responsible for marketing, promoting and selling service agreements to customers for warranties that expire during the Lead Generation Period. Medtronic shall be responsible for marketing, promoting and selling service agreements to customers for warranties that expire during the Distribution Period.

 

(b)         Mazor shall be responsible for providing all necessary service and maintenance for the Mazor X Systems including, without limitation, all installations and warranty repairs for new systems, preventative maintenance, repairs up to and including full system replacement if necessary, and Software Updates, phone and email support, returns, field corrective actions, service tools and calibrations, and spare parts processing and shipping for: (i) Mazor X Systems during the warranty period; (ii) for Mazor X Systems after the warranty period for customers under active service agreements; and (iii) for Mazor X Systems after the warranty period for customers not under active service agreements, on a time and materials basis agreed upon between the customer and Mazor.

 

21

  (c)         Mazor shall ensure phone support capability to an average answer time of 60 seconds between core hours of 8:00 a.m. Eastern Time to 5:00 p.m. Western Time, Monday through Friday, and with twenty-four (24) hour on-call support for patient-on-the-table emergencies.

 

  (d)         Throughout the Distribution Period, Mazor shall ensure:

 

(i)            [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

(ii)           [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

(iii)          [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

(iv)          [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

(v)           [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

(vi)          [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

The Parties acknowledge and agree that the foregoing service requirements may need to be discussed with a view to modification in those countries in which a low number of Mazor X Systems are sold.

 

22

  (e)         For the five (5) non-clinical demo Mazor X Systems owned currently by Medtronic, Mazor shall offer service agreements to Medtronic at the end of the warranty period for [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] per system per year.  For the ten (10) clinical Mazor X Systems owned currently by Medtronic, Mazor shall offer service agreements to Medtronic at the end of the warranty period for [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] per system per year for the first two years and [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] per system per year thereafter.  For any future Mazor X System placed at a customer site by Medtronic, and where Medtronic must bear the burden of paying for service, Mazor shall offer service agreements to Medtronic at the end of the warranty period for [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] per system per year.

 

14.2.          By Medtronic.

 

(a)         Medtronic shall be responsible for responding directly to requests for support from end users and directing such end users to Mazor.  For customers that have purchased a service contract or that are in the warranty period, Medtronic shall have no responsibility for, nor shall Medtronic incur any costs for, providing any service or maintenance including without limitation, preventative maintenance, repairs, and Software Updates.

 

  (b)        With the exception of service agreements sold by Mazor pursuant to Section 14.1(a)above, Medtronic shall sell renewal service agreements for the Mazor X System at the pricing provided in Mazor’s then-current services price list.  For each such renewal service agreement sold by Medtronic, Medtronic shall pay to Mazor an amount equal to [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] of the amount received by Medtronic, but at a minimum shall pay Mazor [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] for service contracts sold in the [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION], and [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] for service contracts sold everywhere else globally.  These minimums may be changed from time to time upon mutual agreement of the Parties., especially in the event that (i) attainable service revenue contract pricing does not allow Medtronic to consistently keep at least [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] of the service contract revenue, or (ii) Mazor is not able to consistently maintain a [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] service margin after a customary initial service period.  Mazor acknowledges that Medtronic does not guarantee that Medtronic will be successful in selling such service agreements.

 

23

	15.	
PRODUCT WARRANTIES

 

15.1.          Mazor hereby represents and warrants to, and covenants with, Medtronic as follows:

 

(a)         Product Warranty.  The Products have been and shall be designed, manufactured, labeled, packaged and sold by Mazor in a manner consistent with good commercial practice and regulations and guidelines of the U.S. Food and Drug Administration for such medical devices, free from defects in material and workmanship, and shall conform to all Applicable Laws and regulations in the Territory relating to medical devices and to the Product’s published specifications and all other applicable manufacturing and Quality System certification requirements, including but not limited to the obligations set forth in Exhibits A-3 and D hereto.  To the knowledge of Mazor, the Products do not infringe upon or misappropriate in any respect any patent, trademark, copyright or any trade secret or other proprietary right of any Person.  The Products shall, for a period of 12 months from installation by Mazor, be free from material defects in material and workmanship and remain in good working order, and function properly and in conformity with the terms of this Agreement and with published specifications and Documentation.  Mazor shall, at the request of Medtronic, its customer or end-user, promptly repair or replace at its sole cost and expense any Product found to be defective (in accordance with the above) within the applicable warranty period.  Mazor further represents and warrants to Medtronic that Mazor’s manufacturing and quality system has been certified to be in compliance with the requirements set forth by the ISO 13485 Standard: Medical Devices – Quality Management Systems – Requirements for Regulatory Purposes. The parties acknowledge that certain issues commonly associated with the introduction of new technology (e.g. instability of mechanical parts, software bugs, issues associated with rigidity, and ergonomics) may occur but that such issues are covered under the warranties provided by Mazor in Sections 15.1(a) and (b).

 

(b)         Software Warranties.  The Software Modules and the software components of the Products shall: (i) operate in accordance with and otherwise conform to the applicable Product specifications and Documentation; and (ii) be free of viruses, malware, malicious code, time bombs, Trojan horses, back doors, drop dead devices, worms, self-replicating or other code of any kind that may alter, destroy, inhibit, disable, or disable or discontinue effective use of the Products; and (iii) not infringe upon or misappropriate in any respect any patent, trademark, copyright or any trade secret or other proprietary right of any Person.  In addition, the Software Customizations shall be of free of viruses, malware, malicious code, time bombs, Trojan horses, back doors, drop dead devices, worms, self-replicating or other code of any kind that may alter, destroy, inhibit, disable, or disable or discontinue effective use of the Products.

 

24

(c)         Medtronic may pass the above warranties from Mazor to its customers and to end-users.  In the event that any Products supplied by Mazor hereunder provided to customers by Mazor do not meet the warranties contained in this Agreement, in addition to all other remedies available hereunder and at law or equity, Mazor shall provide at no charge replacement Products and/or the necessary repairs and/or services required to attain the levels or standards set forth in said warranties.

 

	16.	
RELATIONSHIP

 

The relationship between Mazor and Medtronic is that of independent contractors.  Nothing contained in this Agreement shall be construed to imply a joint venture, partnership, or principal-agent relationship between the Parties; and neither Party by virtue of this Agreement shall have any right, power or authority, express or implied, to act on behalf of or enter into any undertaking binding the other Party.  Mazor and Medtronic shall each refrain from any such representations.  All costs of each Party’s operations, including but not limited to salaries, wages, taxes (corporate, service, employment, franchise, etc.) and employee benefits of each Party and its employees shall be paid solely by such Party, and the other Party hereto shall have no liability or responsibility therefore.

 

	17.	
TERM AND RENEWAL

 

Subject to earlier termination as provided in Section 18 hereof, the term of this Agreement shall commence on the Original Effective Date and continue in full force and effect until the final day of Distribution Year 5 (the “Term”); provided, however, that the Term shall automatically be renewed for an additional three (3)-year period (“Renewal Term”) if during Distribution Year 5 (a) Medtronic shall have sold a number of Mazor X Systems that is greater than the Distribution Year 5 Sales Amount or (b) Medtronic shall have sold a number of Mazor X Systems that is greater than the Sales Cure Amount applicable to Distribution Year 5 and, prior to the end of Distribution Year 5, either (i) made payment to Mazor of the Sales Cure Payment Amount applicable to Distribution Year 5 or (ii) purchased for its own account that number of Mazor X Systems by which the Minimum Sales Amount applicable to Distribution Year 5 exceeds the number of Mazor X Systems sold by Medtronic during Distribution Year 5; provided, further, that at any time, this Agreement may be extended by the mutual written agreement of the Parties.  At the commencement of the Renewal Term, if any, the Parties shall negotiate in good faith with respect to the prices for the Products and any other terms.

 

25

	18.	
TERMINATION

 

18.1.          Medtronic may terminate this Agreement at any time after the twenty-four (24)-month anniversary of the commencement of the Distribution Period upon twelve (12) months’ written notice (a “Medtronic Discretionary Termination Notice”) to Mazor (i.e., termination cannot be effective until at least thirty-six (36) months after the commencement of the Distribution Period); provided, however, that following delivery by Medtronic of a Medtronic Discretionary Termination Notice:

 

(a)         Medtronic will use commercially reasonable efforts to sell the Products during the twelve (12) months following delivery by Medtronic of the Medtronic Discretionary Termination Notice that are substantially equivalent to the efforts used by Medtronic during the twelve (12) months prior to delivery by Medtronic of the Medtronic Discretionary Termination Notice and will not make any material changes to the compensation plans of the Medtronic Sales Representatives responsible for selling the Products; provided, that Mazor’s sole remedy for any actual or claimed breach by Medtronic of this Section 18.1(a) shall be termination in accordance with Sections 18.2 and 18.4, as applicable;

 

(b)         Medtronic’s exclusive right to distribute the Products in the Exclusive Territories will automatically, upon delivery by Medtronic of the Medtronic Discretionary Termination Notice, become non-exclusive, and Mazor will thereafter have the right to sign sales, marketing and distribution agreements with Persons other than Medtronic;

 

(c)         Medtronic’s obligation to pay Implant Fees shall remain in effect throughout the twelve (12) months following delivery by Medtronic of the Medtronic Discretionary Termination Notice; and

 

(d)         Notwithstanding anything herein to the contrary, Mazor will have the right to solicit for employment any employee of Medtronic that is a former employee of Mazor.

 

18.2.          Mazor may terminate this Agreement by delivering written notice within thirty (30) days following the end of a Distribution Year if, during such Distribution Year, Medtronic shall not have sold a number of Mazor X Systems in such Distribution Year that is equal to or greater than the Minimum Sales Amount applicable to such Distribution Year, unless during such Distribution Year, Medtronic shall have sold that number of Mazor X Systems in such Distribution Year that is at least eighty percent (80%) of the Minimum Sales Amount applicable to such Distribution Year (the “Sales Cure Amount”) and, within ten (10) Business Days following the end of such Distribution Year, either (i) made payment to Mazor of that portion of the Sales Cure Payment Amount applicable to such Distribution Year that is payable at such time if Medtronic elects to pay the Sales Cure Payment Amount or (ii) delivered a firm purchase order for that number of Mazor X Systems by which the Minimum Sales Amount applicable to such Distribution Year exceeds the number of Mazor X Systems sold by Medtronic during such Distribution Year (such purchase, a “Distribution Continuation System Purchase”); provided, however, that the Mazor X Systems purchased by Medtronic in connection with such Distribution Continuation System Purchase shall not count as sales in subsequent Distribution Years, or alternatively, Mazor may, in lieu of terminating this Agreement pursuant to this Section 18.4 and upon delivery of written notice within the thirty (30)-day period described above, convert all Territories that are Exclusive Territories at the time of the delivery of such notice to Non-Exclusive Territories.

 

18.3.          Mazor may terminate this Agreement by delivering written notice within thirty (30) days of the consummation of a Change of Control of Mazor or Medtronic.

 

26

18.4.          Each Party shall have the right to terminate this Agreement if the other Party is in uncured material breach of any term or condition herein; provided, with respect to Mazor, a breach of the following sections of this Agreement shall not be considered a “material breach” giving rise to the right to terminate this Agreement: Sections  4.4(d), 8.8, 8.9, and 8.10.  A Party that materially breaches this Agreement shall be given written notice of such breach by the other Party and shall have the opportunity to take remedial action within a period of thirty (30) days or other longer period defined in such notice.  If the breaching Party fails to remedy the breach within such thirty (30) day or other longer defined period, the other Party shall have the right to terminate this Agreement upon ten (10) days written notice to the breaching Party.

 

18.5.          If either Party becomes insolvent or files, or has filed against it, any petition under any bankruptcy or insolvency law or similar law which is not dismissed or stayed within sixty (60) days, is adjudged bankrupt or insolvent or the like, makes or attempts to make an assignment for the benefit of creditors or the like, or a trustee in bankruptcy or a receiver is appointed for either Party, the other Party shall have the right to immediately terminate this Agreement.

 

	19.	
EFFECT OF TERMINATION

 

19.1.          Any expiration or termination of this Agreement shall not alter the rights, duties and obligations of the Parties for any purchase orders placed by Medtronic, or amounts due, prior to the date of such expiration or termination, nor shall it affect the rights of end-users of the Products to continue using the Products.

 

19.2.          Following termination or expiration of this Agreement for any reason, then, in addition to any other rights and remedies available at law, in equity or otherwise, Medtronic may, at its option, sell its inventory of Products within the Territory.

 

19.3.          Within thirty (30) days of termination or expiration of this Agreement, Medtronic shall deliver to Mazor (i) any Qualified Leads not previously delivered to Mazor and (ii) a list (including contact information) of all customers that purchased Products from Medtronic during the Term.  Following termination or expiration of this Agreement, Medtronic shall, at Mazor’s sole cost and expense, cooperate with Mazor as reasonably requested with respect to (a) the completion of any in progress regulatory approvals and (b) the transfer to Mazor of any regulatory approvals held or maintained by Medtronic.

 

19.4.          Notwithstanding the termination or expiration of this Agreement, it is acknowledged and agreed that those rights and obligations which, by their nature, are intended to survive such expiration or termination shall survive, including Sections 1, 3.1(g), 4.4, 4.5, 7.2, 8.6, 11, 12, 13, 14.1(a), 14.1(b), 15, 18.1(a), 19, 22.3, the last sentence of each of Section 22.4(a) and Section 22.4(b), and Sections 22.5, 24(f), 25, 26, 27, 29 and 30.

 

27

	20.	
QUALITY AND REGULATORY MATTERS

 

20.1.          Product Modifications.  Mazor reserves the right to control all decisions relating to the functionality and engineering of the Products and to discontinue or modify the Products and their specifications subject however to Mazor’s obligations in Section D.2.8 (Document Controls and Changes) of the Quality Agreement.

 

20.2.          Mazor will be responsible for obtaining and maintaining (i) all necessary FDA Regulatory Approvals required in the United States and (ii) CE marking (commencing on a date determined by Mazor in 2017).  Medtronic will be responsible for obtaining and maintaining all other Regulatory Approvals that may from time to time be required by Applicable Law, including those required throughout Europe; except to the extent Applicable Law requires Mazor as manufacturer to be responsible for such Regulatory Approval.  Mazor and Medtronic will use commercially reasonable efforts to obtain and maintain all necessary Regulatory Approvals in all additional jurisdictions within any Territory; provided, that in those countries where Mazor will hold the regulatory approval certificate in its name, Mazor will take the lead in obtaining regulatory clearance and Medtronic will provide reasonable assistance to Mazor.  In those countries where Medtronic will hold the regulatory approval certificate in its name, Medtronic will take the lead in obtaining regulatory clearance and Mazor will provide reasonable assistance to Medtronic.  In any case, Mazor will provide, free of charge, samples of Accessories, data and investigation reports and all other documentation that it possesses to the extent that they are required by Applicable Law and will facilitate registration throughout the Territory.  [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

20.3.          The quality assurance and regulatory provisions relating to the Products are in the Quality Agreement set out in Exhibit D.

 

	21.	
DEVELOPMENT PROJECTS

 

21.1.          The parties will conduct certain development activities during the Term in accordance with the following short and long-term development plans.

 

 (a)          [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

 (b)         [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] Medtronic will deliver to Mazor a development plan detailing the scope of such project within one-hundred and eighty (180) days from the Original Effective Date.  All such development work will be performed by Mazor at Medtronic’s sole expense, with such Development Expenses to be reimbursed to Mazor, and Medtronic will cooperate and support such development activities.

 

 (c)          Medtronic recognizes the long-term nature of this Agreement and it is Medtronic’s intention to work exclusively with Mazor to develop future generations of the spinal robotics platforms during the Term and any non-competition period pursuant to Section 27.

 

 (d)          The statement of work for Mazor X Navigation and Guidewireless Program will be as provided in Exhibit E, Statement of Work #1.

 

28

 (e)          The parameters of, and funding for, all future research and development projects will be as negotiated by both parties in good faith and embodied in written statements of work signed by the parties, with the general understanding that (i) for work intended to primarily benefit Medtronic customers, Medtronic will fund the Mazor portion of that work, and (ii) for work intended to primarily benefit any implant manufacturer, Mazor will fund the Mazor portion of that work.  The parties acknowledge that the majority of future research and development projects will be intended to primarily benefit Medtronic customers as contemplated by clause (i) above. In instances where Medtronic funds the Mazor portion of any work, once the project is scoped and quoted and reflected in a statement of work, overall time and materials spent on the project will not exceed the quote plus [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION].  If major changes to the statement of work are made after the quote, both parties will work together to rescope and requote the work.

 

21.2.          Pricing Changes Resulting From Hardware and Software Changes.

 

 (a)          Hardware additions to the Mazor X System resulting from Mazor X Navigation and Guidewireless Program will be added to the transfer price at [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION].  Software additions to the Mazor X System resulting from Mazor X Navigation and Guidewireless Program will [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION].

 

 (b)          For hardware upgrades beyond Mazor X Navigation and Guidewireless Program:  For non-quality related hardware design changes requested by Medtronic as part of a research and development project which change Mazor’s cost of goods, both parties will work together to adjust the transfer price such that Mazor maintains a [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] cost-to-Medtronic margin and Medtronic maintains a [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] cost-to-customer margin.  Mazor will have open book pricing with Medtronic and Medtronic will have open end-user pricing with Mazor for the purposes of adjusting the transfer price.

 

 (c)          Software Updates will be provided to a customer at no charge if the customer purchased a service agreement.

 

 (d)          Software upgrades:  Prior to the initiation of any software upgrade project, the parties will decide and document in a statement of work whether Medtronic believes it can charge its customers for the new functionality or whether the new functionality is simply a new ticket-to-play.  If Medtronic believes it can charge the customer for the new functionality, a transfer price increase will be agreed to by both parties.  If Medtronic believes it cannot charge the customer for the new functionality, the transfer price will not change.

 

29

	22.	
INTELLECTUAL PROPERTY

 

22.1.          Medtronic Intellectual Property.  As between the Parties, Medtronic owns all right, title and interest throughout the world in and to any Medtronic Background IP, any Medtronic Development IP and Medtronic’s Confidential Information and Mazor acknowledges that under this Agreement, Mazor shall acquire no right, title, or interest in or to any of the foregoing, or any other intellectual property rights that are owned or controlled by Medtronic, by implication, estoppel or otherwise.

 

22.2.          Mazor Intellectual Property.  As between the Parties, Mazor owns all right, title and interest throughout the world in and to any Mazor Background IP, any Mazor Development IP and Mazor’s Confidential Information, and Medtronic acknowledges that under this Agreement, Medtronic shall acquire no right, title, or interest in or to any of the foregoing, or any other intellectual property rights that are owned or controlled by Mazor, by implication, estoppel or otherwise.

 

22.3.          Joint Development.  Mazor and Medtronic shall jointly own all right, title and interest, including all intellectual property rights, in and to any Joint Invention. Unless otherwise specified in this Agreement, or by law, each of the Parties, as owners of a joint and undivided interest in the Joint Invention, shall have the right to fully exploit (including by way of sublicense and sale of such ownership rights) such Joint Invention, and all intellectual property rights thereto without an accounting or obligation to the other Party and for the avoidance of doubt, unless otherwise specified in this Agreement or by law, nothing in this Agreement shall limit either party’s rights to use Joint Inventions during or after the Term of this Agreement.    For the avoidance of doubt, a Joint Invention that is a part of a Hardware Customization shall still be considered a Joint Invention.

 

22.4.          Licenses.

 

(a)         Mazor hereby grants to Medtronic a non-exclusive, nontransferable, royalty-free license in the Territory to use Mazor Background IP, Mazor Development IP, Software Modules and Software Customizations during the Term of this Agreement in connection with Products supplied by Mazor and in accordance with this Agreement in connection with advertising, promoting, marketing, distributing and selling the Products and complying with its regulatory requirements hereunder.  Without limitation, Medtronic may (i) (a) use, reproduce, distribute and translate, and (b) modify and otherwise create derivative works of the Promotional Materials as approved by Mazor or the Steering Committee in furtherance of Medtronic’s marketing activities under this Agreement, and (ii) use and reproduce Mazor trademarks associated with the Products in accordance with any written trademark usage guidelines as provided by Mazor.    Medtronic acknowledges and agrees that the use of any Mazor trademarks in connection with this Agreement shall not create any right, title or interest, in or to the use of the trademarks and that all such use and goodwill associated with the Mazor trademarks will inure to the sole benefit of Mazor.  The licenses in this subsection 22.4(a) shall (x) during the Lead Generation Period, be non-exclusive to Medtronic; and (y) during the Distribution Period with respect to the Mazor X and the Software Modules, be exclusive to Medtronic in the Exclusive Territory and non-exclusive to Medtronic in the Non-Exclusive Territory.  In the event that Medtronic or any of its sub-dealers or sub-distributors obtains any registrations for or common law rights to Mazor’s trademarks or other designations of source or origin of Mazor, Medtronic shall assign, or take any action necessary, to cause such sub-dealer or sub-distributor to assign, any and all rights in such trademarks or other designations of source or origin to Mazor, with Mazor to provide any reimbursement to such parties for the actual registration expenses of such assignments to Mazor.  For clarification and notwithstanding any other provision of this Agreement, Medtronic shall have no rights to use any Mazor Background IP, Mazor Development IP, Software Modules or Software Customizations after the Term of this Agreement.

 

30

(b)         Medtronic hereby grants to Mazor a non-exclusive, nontransferable, royalty-free license in the Territory to use Medtronic Background IP and Medtronic Development IP during the Term of this Agreement and in accordance with this Agreement solely for purposes of integrating Medtronic Background IP and Medtronic Development IP into the Software Customizations pursuant to Section 21.  For clarification and notwithstanding any other provision of this Agreement, Mazor shall have no rights to use any Medtronic Background IP or Medtronic Development IP after the Term of this Agreement.

 

(c)         Mazor may use Medtronic’s trademarks, as made available by Medtronic, in connection with its advertising, promotion, marketing, distribution, and sale of the Products and necessary regulatory filings; provided that any such use by Mazor shall be subject to Medtronic’s prior review and approval and in accordance with any written trademark usage guidelines provided by Medtronic.  Mazor acknowledges and agrees that the use of any Medtronic trademarks in connection with this Agreement shall not create any right, title or interest, in or to the use of the trademarks and that all such use and goodwill associated with the Medtronic trademarks will inure to the sole benefit of Medtronic.

 

(d)         The foregoing licenses remains subject to each Party’s obligations with respect to Confidential Information and no other licenses to any Mazor Background IP, Mazor Development IP, Medtronic Background IP, or Medtronic Development IP are granted, and none are to be implied.

 

22.5.          Ownership and Use of Customizations. The Software Customizations shall be deemed Mazor Development IP provided however that Mazor shall have no right to use, license, or otherwise distribute Software Customizations after termination of this Agreement.  The parties acknowledge that in the course of developing Software Customizations, Mazor may also develop Hardware Customizations.  The parties further acknowledge that Hardware Customizations (i) shall be deemed Mazor Development IP, and (ii) nothing in this Agreement shall restrict Mazor’s rights to use such Hardware Customizations during or after the Term of this Agreement.

 

31

22.6.          Obligations to Prosecute and Maintain.  Mazor shall, subject to its reasonable business judgment or consistent with its past practices, prosecute and maintain its rights with respect to the Mazor Background IP and any Mazor Development IP including but not limited to (a) filing applications for registration of patents covering inventions in the Mazor Background IP or any Mazor Development IP with in any jurisdiction in which Mazor manufacturers or has manufactured the Products and in any event in the U.S. and Europe, prosecuting such applications to issuance, and maintaining any issued patents covering the Mazor Background IP or any Mazor Development IP  (including continuations or modifications thereof); and (b) taking reasonable steps to maintain the trade secret status of any trade secrets within the Mazor Background IP and any Mazor Development IP.

 

	23.	
REPRESENTATIONS, WARRANTIES AND COVENANTS OF MEDTRONIC

 

Medtronic hereby represents, warrants and covenants to Mazor that:

 

(a)         Medtronic is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, and is duly qualified to do business in all jurisdictions where it does business, and has all requisite corporate power and authority to execute, deliver and perform the terms of this Agreement.

 

(b)         The execution, delivery and performance of the obligations of this Agreement have been validly authorized by all necessary corporate action of the Medtronic, and this Agreement represents the Medtronic’s valid and legally binding obligation.

 

(c)         Medtronic has due and proper authority to make and perform all duties and obligations set forth and envisioned by this Agreement.

 

(d)         Each of Medtronic’s employees assigned to perform services under this Agreement shall have the proper skill, training and background so as to be able to perform in a competent and professional manner and all work will be performed in accordance with the standards set forth in this Agreement.

 

	24.	
REPRESENTATIONS, WARRANTIES AND COVENANTS OF MAZOR

 

Mazor hereby represents, warrants and covenants to Medtronic that:

 

(a)         Mazor is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, and in all jurisdictions where it does business, and has all requisite corporate power and authority to execute, deliver and perform the terms of this Agreement.

 

(b)         The execution, delivery and performance of the obligations of this Agreement have been validly authorized by all necessary corporate action on the part of Mazor, and this Agreement represents Mazor’s valid and legally binding obligation.

 

(c)          Each of Mazor’s employees assigned to perform services under this Agreement shall have the proper skill, training and background so as to be able to perform in a competent and professional manner and all work will be performed in accordance with the standards set forth in this Agreement.

 

32

(d)         Mazor does not have any obligations or liabilities that might reasonably be expected to have a material adverse effect on its ability to perform its obligations hereunder.

 

(e)         There are no actions, suits, or proceedings instituted or pending or, to the best knowledge of Mazor’s management, threatened against Mazor that might reasonably be expected to have a material adverse effect on the ability of Mazor to perform its obligations hereunder.

 

(f)          Mazor represents and warrants that the manufacture, use, sale and provision of the Products by Mazor, and Medtronic’s use and distribution of the Products as contemplated under this Agreement, will not infringe or violate the patent, copyright, or other property or proprietary rights of any third party, except that the warranty in this subsection does not apply to any infringement or violation to the extent such infringement results from a combination of the Products with Medtronic Development IP or Medtronic Background IP.  Medtronic will provide Mazor with notice of any claim or allegation that would implicate the warranty this Section 24(f) as soon as practicable but in no event more than thirty (30) days after receipt of such claim or allegation provided however that if Medtronic fails to notify Mazor within such period, Mazor’s obligations under this section shall be reduced only to the extent Mazor is prejudiced by such delay. Mazor shall defend, indemnify and save harmless Medtronic, and at Medtronic’s request in its sole discretion from all damages, costs and expenses related to a claim that the Product infringes a patent or other intellectual property right of any third party provided however that Mazor shall have no liability for, nor shall Mazor indemnify Medtronic against, any infringement claim to the extent it is based on the Medtronic Development IP and/or Medtronic Background IP.  If the use of any Products is enjoined, at Mazor’s option, Mazor may at its expense, work to either substitute a fully functionally equivalent product or process (as applicable) not subject to such injunction, modify such Product or process (as applicable) so that it is no longer subject to such injunction, or obtain the right to continue using and distributing such Product or process (as applicable) so long as such Product or process meets all regulatory requirements.

 

(g)         Mazor represents that it has due and proper authority to make and perform all duties and obligations set forth and envisioned by this Agreement.

 

33

	25.	
INDEMNIFICATION.

 

25.1.          Medtronic shall indemnify and defend Mazor, its affiliates, and their respective directors, officers, representatives, employees, agents, subcontractors, successors and assigns, against and hold them harmless from any liability, damage, cost or expense resulting from any claim made by any third party (including without limitation any claim alleging personal injury or property damage) arising from or attributable to:

 

(a)          any breach of this Agreement by Medtronic;

 

(b)          any intentional or negligent act or omission of Medtronic, its employees, agents, subcontractors, sub-dealers or sub-distributors in connection with the performance of this Agreement, including with respect to negligence on the part of Medtronic’s sales or clinical teams; and

 

(c)          any case support, or other services provided by Medtronic in connection with the Products;

 

except to the extent that such claim is caused by the negligence or willful misconduct of Mazor, its employees, agents, or subcontractors.

25.2.          Mazor shall indemnify and defend Medtronic, its affiliates, and their respective directors, officers, representatives, employees, agents, subcontractors, successors and assigns, against and hold them harmless from any liability, damage, cost or expense resulting from any claim made by any third party (including without limitation any claim alleging personal injury or property damage) arising from or attributable to:

 

(a)          any breach of this Agreement by Mazor;

 

(b)          any intentional or negligent act or omission of Mazor, its employees, agents, or subcontractors in the performance of this Agreement;

 

(c)          services (including, without limitation, warranty services or services under a services agreement) to a customer or end user;

 

(d)          defects in design or manufacture of the Products; and

 

(e)          any Product recalls or replacements by any competent Governmental Authority or otherwise deemed appropriate by mutual agreement of Mazor and Medtronic;

 

except to the extent such claim is caused by the negligence or willful misconduct of Medtronic.

34

	26.	
CONFIDENTIALITY AND NON-DISCLOSURE

 

26.1.          Both Parties acknowledge and agree that this Agreement creates a confidential relationship between Medtronic and Mazor and that information concerning both Parties’ business affairs, customers, vendors, finances, properties, methods of operations, computer programs and documentation, diagrams, verbal and written disclosures, drawings, samples, technical descriptions, specific configurations, dimensions, materials, concepts, developments, techniques, know-how, inventions, and other such materials and  information, whether written or oral, is confidential in nature.  All such information is hereinafter collectively referred to as “Confidential Information.”  Neither Party will use, directly or indirectly, for its own benefit or the benefit of others, both during the Term of this Agreement and subsequent to its termination, any Confidential Information of the other Party which may be acquired or developed in connection with or as a result of the performance of this Agreement without the prior written consent of the other Party.

 

26.2.          Both Parties agree, except as directed by the other Party or provided in this Section 26.2, not to disclose any Confidential Information of the other Party to any Person whatsoever at any time during or after the Term of this Agreement.  Upon termination of this Agreement and at a Party’s written request, each Party will turn over to the other Party all documents, papers and other matter in its possession or control that relate to the other Party or the Intellectual Property of the other Party.   Both Parties further agree to bind its employees and subcontractors to the terms and conditions of this Agreement.  Each Party acknowledges that disclosure of any Confidential Information of the other Party by it may give rise to irreparable injury to the other Party, its subsidiaries and/or affiliated companies or the owner of such information, inadequately compensable in damages.  Accordingly, the disclosing Party may seek and obtain injunctive relief against the breach or threatened breach of the foregoing undertakings, in addition to any other legal remedies that may be available.  Each Party acknowledges and agrees that the covenants contained herein are necessary for the protection of legitimate business interests of the other Party, its subsidiaries and/or affiliated companies and are reasonable in scope and content.

 

26.3.          Each Party’s obligation of non-disclosure and non-use shall not apply to information (i) which at the time of its disclosure to the receiving Party is available to the public, (ii) which the receiving Party can show was in its possession prior to disclosure, (iii) that is published or otherwise becomes available to the public through no fault of the receiving Party, (iv) that the receiving Party can show was received by it from a third party without breach of a confidential obligation, (v) is independently developed by the receiving Party without use of any Confidential Information of the other Party, or (vi) is required to be disclosed by any governmental agency, provided that the disclosing Party shall give the other Party reasonable notice of such requirement and shall afford the other Party the opportunity to prevent such disclosure.

 

26.4.          Notwithstanding anything to the contrary in this Section 26, each of the Parties to this Agreement hereby agrees with the other Parties hereto that, except as may be required to comply with the requirements of applicable law and the Tel Aviv Stock Exchange (TASE) or New York Stock Exchange or NASDAQ, no press release or similar public announcement or communication will be made or caused to be made concerning the execution or performance of this Agreement unless specifically approved in advance by Medtronic and Mazor.  The foregoing shall not restrict Medtronic’s and Mazor’s internal communications with their respective employees and advisors.

35

 

	27.	
NON-COMPETITION

 

During the Restricted Period, each of Medtronic and Medtronic Parent agrees not to, and agrees to cause each of their Affiliates not to, develop, co-develop, fund, acquire, manufacture, market, distribute or sell, independently or with a third party, anywhere in the world a robotic surgical system for spinal applications; provided, however, that if Medtronic delivers a Medtronic Discretionary Termination Notice at any time following the twenty-five (25) month anniversary of the commencement of the Distribution Period, this Section 26.3 shall not prevent any of Medtronic, Medtronic Parent or any of their Affiliates from, immediately following delivery of such Medtronic Discretionary Termination Notice, developing, co-developing, funding or manufacturing (but not marketing, distributing or selling) a surgical guidance system for spinal applications.  The Parties acknowledge and agree that the foregoing restriction is reasonable considering the circumstances of the relationship between the Parties and the mutual desire to effectively commercialize the Mazor technology and that, if the arbitral panel contemplated by Section 30.2 determines the restriction is unreasonable, then the Parties agree that the maximum period, scope or geographical area reasonable under the circumstances shall be substituted for the stated period, scope or area.  If Medtronic, Medtronic Parent or any of their Affiliates breaches, or threatens to commit a breach of, any of the provisions of this Section 26.3, Mazor shall have the following rights and remedies, each of which rights and remedies shall be independent of the others and severally enforceable, and each of which is in addition to, and not in lieu of, any other rights and remedies available to Mazor at law or in equity: (i) the right and remedy to have this Section 26.3 specifically enforced by any court of competent jurisdiction, it being agreed that any breach or threatened breach of this Section 26.3 would cause irreparable injury to Mazor and that money damages would not provide an adequate remedy to Mazor; and (ii) the right and remedy to require the breaching party to account for and pay over to Mazor any profits, monies, accruals, increments or other benefits derived or received as the result of any transactions constituting a breach of this Section 26.3.

 

	28.	
ASSIGNMENT

 

This Agreement shall be binding upon the Parties’ respective successors and permitted assigns.  Neither Party may assign or subcontract, without the prior written consent of the other Party, any of its rights, duties or obligations under this Agreement to any Person, in whole or in part, and any such attempted assignment or subcontracting shall be null and void; provided, however, that Mazor may: (i) assign this Agreement, or any rights or obligations hereunder, to its Affiliates without the written consent of Medtronic; (ii) use any of its United States domiciled Affiliates to perform any of its obligations under this Agreement that need to be performed in the United States; and (iii) subcontract its manufacturing obligations under this Agreement.  For clarity, if a Party experiences a Change of Control, such Change of Control shall not constitute an assignment of this Agreement.

 

36

	29.	
NOTICES

 

Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered by (a) personal delivery, (b) expedited delivery service, (c) facsimile transmission or (d) certified or registered mail, postage prepaid, addressed as follows:

 

If to Medtronic:

 

Scott Shaver

Medtronic Navigation, Inc.

826 Coal Creek Circle

Louisville, CO 80027

Phone: (720) 890-3283

With a copy to:

Scot M. Elder

Vice President and Chief Legal Counsel, RTG

Medtronic Xomed, Inc.

6743 Southpoint Drive North

Jacksonville, FL 32216

Telephone: (904) 332-2485

Facsimile: (904) 332-8914

If to Mazor:

 

Mazor Robotics Ltd.

5 Shacham Street, North Industrial Park, 3088900 Israel

Attn: Sharon Levita

Title: Chief Financial Officer

Telephone: 972 4 6187103

Facsimile: 972 4 6187111

With a copy to:

Salinger, Confino, Ben-Zvi, Luchtenstein, Law Offices

5 Azrieli Center

Square Tower, 35th Floor

Tel Aviv 6702501 Israel

Attn: Barak Luchtenstein, Advocate

Telephone: 972 3 71887700

Facsimile: 972 3 7188701

Each Party may, by notice given in accordance with this Section 29 to the other Party, designate another address or person for receipt of notices.

 

37

	30.	
GENERAL PROVISIONS

 

30.1.          Governing Law. This Agreement shall be governed by, and enforced and construed in accordance with, the laws of the State of Delaware without regard to its conflicts of law provisions.  The United Nations Convention for the International Sale of Goods shall not apply to the transactions contemplated herein.  No failure or delay by a Party to exercise any right or remedy provided under this Agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy. If any provisions herein are found to be unenforceable on the grounds that they are overly broad or in conflict with Applicable Laws, it is the intent of the Parties that such provisions be replaced, reformed or narrowed so that their original business purpose can be accomplished to the extent permitted by Applicable Laws, and that the remaining provisions shall not in any way be affected or impaired thereby.  The provisions of this Agreement shall be severable and the invalidity or unenforceability of one provision shall not affect any other provision of this Agreement.

 

30.2.          Dispute Resolution and Arbitration.  Except as provided in Section 26.3, in the event of any controversy or dispute arising out of or relating to any provision of this Agreement, or the construction, validity or breach thereof (a “Dispute”), the Parties shall try to settle the Dispute amicably between themselves, through the Steering Committee and/or Executive Sponsors.  If the Parties fail to settle such Dispute within thirty (30) days after written notice of such Dispute by one Party to the other Party, such matter may be referred by either Party to be exclusively and finally resolved by binding arbitration in accordance with the following provisions. Either Party may demand in writing such arbitration by sending a notice to arbitrate to the other Party and to the American Arbitration Association (the “AAA”), which shall administer the arbitration under its Commercial Arbitration Rules then in effect.  In no event may any demand for arbitration be filed after the running of any applicable statute of limitation. The arbitration shall be held at the AAA’s offices located in the State of New York. The law applicable to the arbitration, including the administration and enforcement thereof, shall be the Federal Arbitration Act (9 USC §§1-16), as amended.  This agreement to arbitrate shall be specifically enforceable in any court of competent jurisdiction. For all Disputes, each Party shall select a neutral third party arbitrator, and the two Party-chosen arbitrators shall select a third neutral arbitrator who shall chair the arbitration panel. The arbitration shall be governed by the express terms of this Agreement and the laws of the State of Delaware.  The arbitral panel shall have the power to grant monetary damages as well as injunctive or other specific relief.  Notwithstanding the foregoing, each Party shall have the right to seek, without establishment of the arbitral panel, injunctive or other provisional relief from a court of competent jurisdiction that may be necessary to avoid irreparable harm or preserve the subject matter of a Dispute.  Each Party shall bear its own costs and expenses and attorneys’ fees, and the arbitral panel may, in its discretion, require the non-prevailing Party to pay the arbitrators’ fees and any administrative fees of arbitration, reasonable attorneys’ fees and costs to the prevailing Party (in proportion to the extent to which the prevailing Party actually prevailed, given all of the monetary and non-monetary claims included within such arbitration), and the other Party shall pay the remainder of such arbitrators’ fees and administrative fees of arbitration; provided that, will respect to any claim brought by Mazor against Medtronic for breach of Section 3.1, 8.1, or 18.2(a) of this Agreement, the arbitral panel will require that the non-prevailing Party pay the arbitrators’ fees and any administrative fees of arbitration, reasonable attorneys’ fees and costs to the prevailing Party.  Any award or portion thereof, whether preliminary or final, shall be in writing, signed by the arbitral panel, and shall state the reasons upon which the award or portion thereof is based. The award rendered by the arbitral panel shall be final and judgment may be entered upon it in accordance with applicable law in any court of competent jurisdiction.  The Parties and the arbitral panel shall treat all aspects of the arbitration proceedings, including discovery, testimony, other evidence, briefs, and the award, as strictly confidential, not subject to disclosure to any third party or entity, other than to the Parties, the arbitral panel, and the AAA.  These arbitration provisions shall survive the termination or expiration of this Agreement.

 

38

30.3.          With effect as of the Effective Date, this Agreement and the Purchase Agreement dated May 18, 2016 (as amended) constitute the entire Agreement between the Parties with respect to the subject matter hereof and supersede all previous proposals, negotiations, representations or commitments between the Parties, both written and oral, including without limitation (i) the Agreement for Mutual Exchange of Confidential Information dated December 7, 2015, and (ii) the Original Agreement.  For the avoidance of doubt, the Original Agreement shall be deemed to have been in effect in accordance with its terms at all times prior to the Effective Date.  The terms of this Agreement shall prevail in the event that there is a conflict or variance with the terms and conditions of any purchase order form or other document submitted by Medtronic or with any invoice or other document submitted by Mazor.

 

30.4.          All rights and remedies conferred under this Agreement or by any other instrument or law shall be cumulative and may be exercised singularly or concurrently.

 

30.5.          The failure by either Party to enforce any term or condition of this Agreement, the written waiver of any term or condition of this Agreement or the acceptance of any payment shall not be deemed a waiver of further enforcement of that or any other term or condition.  No course of dealing between the Parties and no delay or omission by either Party in exercising any right or remedy hereunder shall operate as a waiver thereof or of any other right or remedy and no single or partial exercise thereof shall preclude any other or further exercise thereof or the exercise of any other right or remedy.

 

30.6.          The captions used herein are for convenience only and shall not be considered in construing or interpreting the provisions hereof.

 

30.7.          If any provision of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.

 

30.8.          This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all such counterparts together shall constitute but one and the same instrument.

 

30.9.          This Agreement shall not be valid until signed and accepted by authorized representative for each Party, and no Party shall be bound by any change, alteration, amendment modification, termination or attempted waiver of any of the provisions hereof unless in writing and signed by an authorized officer of the Party against whom it is sought to be enforced.  This Agreement shall be binding on and inure to the benefit of the Parties hereto and their respective successors, legal representatives and permitted assigns.

 

30.10.        Nothing in this Agreement, whether express or implied, is intended to confer any rights or remedies under or by reason of this Agreement on any Person other than the Parties to this Agreement and their respective successors and permitted assigns.

 

30.11.        In this Agreement, except to the extent otherwise provided or that the context otherwise requires: (a) when a reference is made in this Agreement to an Article, Section, Exhibit or Schedule, such reference is to an Article or Section of, or an Exhibit or Schedule to, this Agreement unless otherwise indicated; (b) the table of contents and headings for this Agreement are for reference purposes only and do not affect in any way the meaning or interpretation of this Agreement; (c) whenever the words “include,” “includes” or “including” are used in this Agreement, they are deemed to be followed by the words “without limitation”; (d) the words “hereof,” “herein” and “hereunder” and words of similar import, when used in this Agreement, refer to this Agreement as a whole and not to any particular provision of this Agreement; (e) all terms defined in this Agreement have the defined meanings when used in any certificate or other document made or delivered pursuant hereto, unless otherwise defined therein; (f) the definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms; (g) references to a Person are also to the Person’s heirs, executors, administrators, personal representatives, successors and permitted assigns, as applicable; and (h) the use of “or” is not intended to be exclusive unless expressly indicated otherwise.

 

39

 

IN WITNESS WHEREOF the Parties hereto have executed this Agreement as of the date above written.

 

	
MEDTRONIC NAVIGATION, INC.

 

By: /s/ Bradley E. Lerman

Name:Bradley E. Lerman

Title:VP and Secretary

Date: 8/29/2017

	 

 

MAZOR ROBOTICS LTD.

	
By: /s/ Ori Hadomi

	 	
By: /s/ Jonathan Adereth

	
Name: Ori Hadomi

	 	
Name: Jonathan Adereth

	
Title: CEO

	 	
Title: Chairman

	
Date: 8/29/2017

	 	
Date: 8/29/2017

 

SOLELY FOR PURPOSES DESCRIBED IN

SECTION 7.2 AND 27 OF THIS AGREEMENT:

MEDTRONIC PLC

By: /s/ Bradley E. Lerman

Name: Bradley E. Lerman

Title: Senior VP, General Counsel and Corporate Secretary

Date: 8/29/2017

 

[Signature page to Lead Sharing and Distribution Agreement]

EXHIBIT A-1

 

PRICING

 

[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

A-1

 

EXHIBIT A-2

 

QUOTAS FOR MAZOR X DISPOSABLE KITS

 

[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

A-2

 

EXHIBIT A-3

 

MAZOR X SPECIFICATIONS

 

[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

A-3

EXHIBIT A-4

 

IMPLANT FEES

 

[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]:

For each Distribution Period of this Agreement, [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] of the Mazor X Systems purchased from Mazor for distribution collectively in these four (4) countries will be designated [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] and will not incur any such Implant Fees.  The designation will be assigned by system serial number.  The designation can be transferred to another system serial number when a system is swapped out at a hospital for quality purposes or placement-to-sale swap out situations.  However, at any given time, the number of Implant Fee free designated systems in the field (excluding the Initial Placed Units), shall not exceed [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION].  For all other Mazor X Systems, the Implant Fee will be [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION], whenever the Mazor X System is used and a Medtronic Spine Construct is implanted.  At the end of each fiscal quarter, the total number of Implant Fee free Mazor X Systems will not exceed [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] of the Mazor X Systems in use in these four (4) countries.

[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]:

The Implant Fee will be [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] for any level case, whenever the Mazor X System is used and a Medtronic Spine Construct implanted.

Remainder of Distribution Territory (including [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]):

The Implant Fee will be [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION].

A-4

EXHIBIT A-5

 

ACCESSORIES

 

	
KIT0776

	
Bed Frame Adaptor

	
KIT0777

	
9" Conversion Kit for Image Adaptor

	
KIT0778

	
Standard Image Adaptor

	
KIT0552

	
Mazor X Surgical Instruments

	
KIT0284

	
4mm x 120mm Schanz Screw, Qty: 10

	
KIT0142

	
SA Reduction Tube, 10 pack

	
KIT0779

	
Reference Marker

	
KIT0780

	
Dual Clamp

	
KIT0729

	
Schanz screw 4mmx80,10 pack

	
KIT0781

	
Universal Screwdriver

	
KIT0782

	
Rear Panel Adaptor

	
KIT0783

	
Screen Arm Adaptor

	
KIT0784

	
Stylus Marker

	
KIT0785

	
Link Bridge

	
KIT0786

	
BM Bridge

	
KIT0787

	
Clamp Link

	
KIT0732

	
Auxiliary Drill Guide And Auxiliary Cannula

	
KIT0788

	
Scalpel Handle

	
KIT0736

	
Long drill guide and Long Cannula

	
KIT0737

	
Short Drill Guide and Short Cannula

	
KIT0789

	
Blunt

	
KIT0738

	
Long drill 3x80mm,10 pack

	
KIT0733

	
Long Drill 3.0x30, 10 pack

	
KIT0734

	
Short Drill 3x30mm,10 pack

	
KIT0739

	
Short Drill 3x80mm,10 pack

	
KIT0735

	
Long drill 4x80mm,10 pack

	
KIT0731

	
Head Pin 2.5x60mm,10 pack

	
KIT0758

	
Head Pin 2.5x100mm,10 pack

	
KIT0790

	
Schanz Bond

	
KIT0791

	
MiniClamp

	
KIT0792

	
Target Extender

	
KIT0793

	
Arm Guide

	
KIT0794

	
Target Extender Screw

	
KIT0795

	
Schanz Arm

	
KIT0740

	
Short Drill 2.4X25mm,10 pack

	
KIT0704

	
Surgical System Sterile Sleeve, 10 Pack

	
KIT0741

	
Surgeon's screen Sterile Sleeve,10 pack

	
KIT0742

	
Sterile Clear Sleeve,10 pack

	
KIT0796

	
Accuracy Pointer

	
KIT0797

	
Iron Man

	
KIT0755

	
Lateral Optional  Kit

	
KIT0574

	
Mazor X Spine Disposable Kit

	
KIT0571

	
Mazor X Scan & Plan Disposable Kit

	
KIT0568

	
Flat Panel Adaptors KIT

	
KIT0685

	
Flat Panel Adaptor Kit B

A-5

 

EXHIBIT B

 

MEDTRONIC SALES AND MARKETING PLAN

 

[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

B-1

 

EXHIBIT C

 

TRAINING COSTS

 

Training during the Lead Generation Period will be as follows:

Surgeon training:

			
The base cost for Surgeon training for a one (1) day training session in the [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] per session and will be split equally between Mazor and Medtronic.  The base costs for each session will include bioskills training, including one (1) cadaver and live surgery case observation, for up to six (6) surgeons. 

			
Air travel, hotel accommodations, ground transportation and meals are not included in the above cost and will be split equally between Mazor and Medtronic.

Medtronic Sales and clinical team training:

			
The base cost for Medtronic Sales Representatives and clinical personnel training for one (1) day training session in the [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] per session and will be paid exclusively by Medtronic.  The base cost for each session will include bioskills training, including one (1) cadaver, for up to twelve (12) Medtronic Sales Representatives and clinical personnel. 

			
Air travel, hotel accommodations, ground transportation and meals are not included in the above cost and will be paid exclusively by Medtronic.

The following Mazor training price list was used to calculate the base costs set forth above:

[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

C-1

EXHIBIT D

 

QUALITY AGREEMENT

 

D.1.         Definitions.

 

“Approved Manufacturing Sites” means the Mazor sites approved by Medtronic for the applicable Product(s) as of May 16, 2016 or otherwise agreed to by the Parties via the change notification section (Sect B.2.8).

 

“Authority” means any government, Notified Body, commission, board, regulatory agency, court or other instrumentality having any jurisdiction over the design, manufacturing, testing, labeling, packaging, use, marketing, sale, storage, shipment and distribution of the Products, or of Medtronic products in which the Products are used.

 

“CAPA” means a corrective action and preventive action system for identifying and preventing or eliminating the cause of an existing or potential nonconformity, defect, or other undesirable situation in order to prevent occurrence or recurrence.

 

“Certificate/Certification of Conformance/Compliance” means a document, signed by an authorized representative of Mazor, attesting that a particular Product is Manufactured or Serviced in accordance with applicable Quality Management System requirements, the Specifications and this Quality Agreement.

 

“Component” means any raw material, substance, piece, part, software, firmware, labeling or assembly which is intended to be included as part of the Product(s) or consumed during the Manufacture of the Product(s).

 

“Control Plan” means a document that identifies key Manufacturing process steps, critical inputs to and critical variables of such steps, and that defines process monitoring control strategies and tools.

 

“Correction(s)” means the repair, modification, adjustment, relabeling, destruction, or inspection (including patient monitoring) of a device without its physical Removal from its point of use to some other location.

 

“Critical Feature” or “CFI” means the process specified by Medtronic for identifying features requiring control.

 

“Design Input” means the physical and performance requirements of the Product(s) that are used as a basis for device design.

 

“Device History Record” or “DHR” means a compilation of Records containing the production history of the Product(s).

 

“Field Action” or “FA” means an activity outlining the steps for management of and/or communication regarding the performance of distributed clinical, custom, and/or market released Product currently in use by the customer.  These activities may include educational briefs, health safety alerts, notifications, Corrections, Removal, or recall of Product(s) in any Medtronic product(s).

 

“Good Manufacturing Practice” or “GMP” means FDA regulations and guidelines regarding manufacturing practices and quality systems, including 21 CFR Part 820.

 

“ISO 13485” means the “ISO Quality Management Systems - Medical Devices - System Requirements for Regulatory Purposes” standard.

 

“ISO 9001” means the “Quality Management Systems - Requirements” standard.

 

“Lot/Batch” means one or more Products Manufactured under essentially the same conditions that are intended to have uniform characteristics and quality within specified limits.

 

“Manufacture(d)” and “Manufacturing” means all steps, processes and activities necessary to produce Product(s), including without limitation, the design, manufacturing, processing, quality control testing, any inspection, release and storage of Product(s) in accordance with the terms and conditions of this Quality Agreement.

 

“Nonconforming Product” means any Product that does not meet the Component or Product Specifications or all the applicable requirements of this Quality Agreement.

 

“Notified Body” means a public or private organization accredited in a member state of the European Union to carry out conformity assessment procedures for some classes of medical devices.

 

“Product(s)” means all goods supplied by Mazor to or for the benefit of Medtronic on or after May 16, 2016.

 

“Qualification” or “Qualify” means activity and analysis performed to demonstrate adherence to the applicable Specifications for the Product. Qualification for a Product means Product testing or inspection conducted according to an approved and controlled protocol to ensure the Product meets Specifications.

 

“Quality System” or “Quality Management System” or “QSR” means the regulatory requirements for the methods used in, and the facilities and controls used for, the design, Manufacture, packing, labeling, storage, installation and servicing of Product.

 

“Records” means written or electronic accounts, notes, data, record of, and information and results obtained from performance of Services of all work done under this Quality Agreement.

 

“Refurbished Material” means used Products or Components that are re-used in the Manufacture of new or modified Products.

 

“Removal” means the physical removal of a device from its point of use to some other location for repair, modification, adjustment, relabeling, destruction, or inspection.

 

D-2

“Services” means the Manufacturing and other activities that Mazor is engaged in to provide to Medtronic under this Quality Agreement.

 

“Specification(s)” means all applicable specifications, drawings, protocols and other documents relative to the design, physical characteristics, function, performance, Manufacture, packaging, labeling and quality of the Product(s).

 

“Sub-tier Supplier” means any supplier, excluding Medtronic and all entities owned by Medtronic, that either directly or indirectly provides any product or services to the Mazor in connection with any Product.

 

“Validation” or “Validate” means confirmation by examination and provision of objective evidence that the applicable requirements can consistently be fulfilled.

 

D.2.         Compliance with Applicable Quality System Requirements.  Mazor shall comply with the following Quality System requirements.

 

D.2.1.      General.  Unless otherwise specifically agreed in writing by Medtronic, all Product supplied under this Quality Agreement shall be Manufactured in accordance with: (a) all applicable ISO 13485 and ISO 9000 standards and applicable ISO-certified processes, including without limitation ISO 13485; (b) FDA 21 CFR Part 820, current GMP; (c) all other quality standards and quality assurance plans referenced in the Specifications; and (d) Medical Device Directive MDD 93/42/EEC to the extent necessary to support CE marking and declarations of conformity to the Essential Requirements of the directive for the Products in scope. Mazor shall also comply with any quality provisions included within the Specification.  Mazor shall notify Medtronic of changes to the status of Mazor certificates that affect the status of the Products.  Mazor shall ensure that entities that supply Components used by Mazor in the production of Products comply with any applicable regulatory provisions and the provisions of this Quality Agreement or any applicable quality provisions included within the Mazor’s Specification or other documentation provided by the Mazor. Mazor shall continue to be in compliance with this Quality Agreement for so long as Mazor provides Products to Medtronic. Mazor shall bear all reasonable costs associated with compliance with this Section.

 

D.2.2.      Quality Management System Requirements. Each Party shall establish and maintain a Quality System that is appropriate for the activities for which the Party is responsible under this Quality Agreement and that is in compliance with Quality Management System requirements.

 

D.2.3.      Management Responsibility.

 

D.2.3.1.          Management and organization.  Mazor shall have personnel with executive responsibility to oversee its quality system. Mazor also shall maintain an organizational structure which ensures the Product(s) are designed, developed and/or manufactured in accordance with this quality agreement.

 

D.2.3.2.          Executive Representative.  Mazor shall assign a person or person(s) with executive responsibility, or who report(s) directly to a person with executive responsibility, to serve as a contact for Medtronic under this Quality Agreement, and to oversee compliance with this Quality Agreement.

 

D-3

D.2.3.3.          Personnel and Training.  Mazor shall have sufficient personnel with the necessary education, background, training and experience to perform under this Quality Agreement.  Training Records shall be maintained by Mazor.

 

D.2.3.4.          Quality Plan.  Mazor shall have a quality plan and/or quality system manual that defines the elements of the Quality System relevant to the design, development and/or Manufacture of the Product(s), and shall establish how the quality requirements shall be met.

 

D.2.4.      Identification.  Mazor shall ensure that Product(s) and Components are identified during all stages of receipt, production and shipping/distribution.  Mazor shall have systems in place that provide a means of identifying the status of Product(s) not yet transferred to Medtronic. At a minimum, identification and segregation is required for:

 

		(i)	
Receiving inspection

 

		(ii)	
Production work-in-progress

 

		(iii)	
Nonconforming Product

 

		(iv)	
Rejected Product

 

		(v)	
On-hold (quarantined) Product

 

		(vi)	
Conforming Product ready for transfer to Medtronic or a Medtronic contract manufacturer

 

D.2.5.      Traceability.  Mazor shall be responsible for setting up and maintaining controlled documentation of Product and Component traceability during all stages of receipt, production and shipping/distribution. Traceability and quality Records shall be maintained in accordance with Section B.15 (Record Production and Retention). Once Products are received by Medtronic, Medtronic shall be responsible for traceability of the Products. Traceability requirements include, but are not limited to the following:

 

D.2.5.1.          Minimum Traceability.  All Products and Components thereof are traced by Lot/batch at a minimum.

 

D.2.5.2.          Each shipment shall include a manifest that identifies at a minimum:

 

		(i)	
Purchase order reference

 

		(ii)	
Quantity released

 

		(iii)	
Product part number

 

		(iv)	
Revision of Product part number.

 

D-4

		(v)	
Serialized Product – The list of serial numbers included in that shipment.

 

		(vi)	
Lot controlled Product – The list of lot number(s) included in that shipment.

 

		(vii)	
Use By Date

 

D.2.5.3.          Process Information.  Process information is traced to all levels of Manufacture. At a minimum, this includes operator performing the operation and date performed, shift (as applicable), Manufacturing instructions used, use of Validated equipment and identification of equipment used, BOM/design revision and configuration, resolution of any discrepancies, and Record of any rework performed.

 

D.2.5.4.          Raw Materials.  Raw material is traced to original material Manufacturing Lot/batch at a minimum.

 

D.2.6.      Corrective and Preventive Actions/Performance.

 

D.2.6.1.          Procedures. Mazor shall establish and maintain procedures for implementing a CAPA system in compliance with the Quality Management System requirements. The CAPA system shall include, at a minimum, the following requirements:

 

		(i)	
Analysis of quality data (e.g., Manufacturing processes, operations, quality audit Records and reports, complaints, returned Product or similar product) to identify root causes of Nonconforming Product or other quality problems.

 

		(ii)	
Investigation of the causes of nonconformities.

 

		(iii)	
Identification of the actions needed to correct the nonconformance and to prevent recurrence.

 

		(iv)	
Verification or validation of the corrective and preventive action.

 

		(v)	
Implementation of and recording changes to methods and procedures needed to correct and prevent quality problems.  Prior notification and approval may be required by Medtronic pursuant to Section B.2.8 (Document Controls and Changes).

 

		(vi)	
Assurance that information concerning quality problems or Nonconforming Product is disseminated to appropriate quality personnel.

 

		(vii)	
Submission of relevant information on identified quality problems, as well as corrective and preventive action, to Mazor management for their review.

 

		(viii)	
Documentation of activities under the CAPA system.

 

		(ix)	
Effectiveness verification of corrective and preventive action.

 

D-5

D.2.6.2.          Resolution.  Mazor shall implement the CAPA system with regard to any quality, Manufacturing or performance issue raised by Mazor or Medtronic related to Product(s). Such efforts may include making appropriate Mazor personnel available (at the Mazor’s expense) at the Mazor and/or Medtronic facilities where such Product quality or performance issues are identified and/or need to be addressed within the timeframe requested by Medtronic.

 

D.2.7.      Nonconforming Product.  With respect to any Product shipped to and inventoried at Medtronic, Medtronic shall have the right, within fifteen (15) Business Days from receipt, to reject any Product that does not meet the specifications or any Applicable Laws or regulations or that is otherwise defective.  With respect to any Product shipped directly to customer sites, Medtronic shall have the right, until the completion of installation, to reject any Product that does not meet the specifications or any Applicable Laws or regulations or that is otherwise defective.  Any such rejection shall be accomplished by a notice from Medtronic identifying and specifying, in reasonable detail, the Product rejected and the reasons for rejection.  Any Product rejected by Medtronic shall be made available, on reasonable notice and during normal business hours, for inspection by Mazor or its representatives in a manner consistent with Mazor’s return authorization procedures established from time to time and as previously communicated to Medtronic.  Mazor will replace any rightfully rejected, unused Product free of charge and will indemnify Medtronic for reasonable direct out-of-pocket expenses (including freight and customs clearance, if any) incurred by Medtronic in connection with (a) shipment of replacement Product to the same location and (b) shipment of the nonconforming Product back to Mazor (if so requested by Mazor and then pursuant to Mazor’s return authorization approval procedures) Mazor will cooperate with Medtronic in working to close of Medtronic CAPA tasks associated with any nonconforming Product.  In the event of a rejection or return of defective Product, Mazor shall promptly notify Medtronic of such rejection or return, as the case may be, ship replacement Product within seven (7) days of its receipt of the rejected Product and consult with Medtronic regarding the necessary analysis to be performed by Mazor.  Mazor shall also be responsible for analyzing material, investigating its own processes, and reporting results to Medtronic within a reasonable period (e.g., 30 Business Days).  In no event will Mazor be responsible for paying Medtronic any indirect or consequential damages arising out of or related to any rejection of a Product pursuant to this Section D.2.7.

 

D.2.8.      Document Controls and Changes.  Mazor shall notify Medtronic through a Medtronic supplier change request system (i.e., the Medtronic Portal) of any material change to Quality Management, business location, acquisition, bankruptcy, Device Component supplier, Product, Product Design/Specification, Manufacturing Process, or Special Processes with respect to the Products.  Changes to product Design, Specification, packaging and/or labeling are required at least sixty (60) days prior to Mazor’s proposed implementation change.  If circumstances allow, Medtronic shall have the option to make a last-time buy of the then-current product revision for the Product and/or product components before such change is implemented.

 

D-6

D.2.9.      Purchasing Controls.  For Components not supplied by Medtronic, Mazor shall establish and maintain controls on the purchase of Components to ensure conformance to specified requirements, including but not limited to visual inspection of packaging, labeling, or shipping containers, and dimensional inspection or analytical testing. Mazor shall maintain documentation that clearly describes the quality requirements for Components, and shall require Component sources to obtain prior written approval from Mazor of any proposed changes in the Manufacturing of the Components prior to making any change. If necessary, Medtronic may choose to also evaluate Mazor’s Component sources to ensure that the purchased materials meet specified purchase requirements.  Mazor shall not use in any Product(s) any Components that are unapproved, counterfeit, or do not meet the applicable Component specification.

 

D.2.10.    Refurbished Material.  Refurbished Material shall only be used in any Product(s) when there is prior written approval from Medtronic, and such approval with not be unreasonably withheld.

 

D.2.11.    Acceptance Activities. Mazor shall establish and maintain acceptance procedures with respect to the Manufacture of the Products.

 

D.2.11.1.        Medtronic Sourcing/Receiving Inspection.  As part of the overall supplier management plan, Medtronic may choose to perform source inspection at the Mazor or receiving inspection on Product(s) that arrive at the Medtronic receiving site.  If Medtronic chooses to perform source inspection at Mazor’s site, Mazor shall provide Medtronic reasonable access to inspect and review the site(s) where the Products are tested, handled, stored, distributed, and/or Manufactured, including access to the Product(s) and all related Records.  Medtronic shall provide prior notice of inspection of not less than twenty (20) days, except when special circumstances warrant a shorter time, such as when patient safety is a concern, in which case the parties shall mutually agree on a time to conduct the source inspection. Medtronic may certify the Mazor’s measurement system process and use the Mazor’s final inspection data submitted through a Medtronic approved system such as the System for Process Intelligence and Capability Excellence (“SPICE”) or Infinity QS system, or equivalent.

 

D.2.11.2.        Mazor Receiving Acceptance. Mazor shall have procedures for acceptance of incoming Component, which shall be inspected, tested, or otherwise verified as conforming to specified Medtronic’s requirements. Mazor shall document acceptance or rejection of incoming Component.

 

D.2.11.3.        In-Process Acceptance. Mazor shall have in-process acceptance procedures, which shall ensure that in-process Product is controlled until the required inspection and tests or other verification activities have been completed, or necessary approvals are received.

 

D.2.11.4.        Final Acceptance. Mazor shall have procedures for finished Product acceptance to ensure that each production unit, Lot, or batch of finished Product meets Medtronic’s acceptance criteria. Finished Product(s) shall be adequately controlled until released.

 

D.2.11.5.        Records.  Mazor shall maintain Records for incoming, in-process and final acceptance activities.

 

D-7

D.2.12.          Packaging and Labeling.

 

D.2.12.1.        Compliance with Specifications.  All Products shall be packaged and labeled in accordance with any applicable Specifications.

 

D.2.12.2.        Procedures.  Mazor shall establish and maintain procedures to control labeling activities in compliance with the Quality Management System requirements.

 

D.2.12.3.        Labels.  Labels and labeling shall comply with any applicable requirements in the Specifications.  Over-labeling of Product is not allowed by either party unless approved by both parties in writing.

 

D.2.12.4.        Label Integrity and Inspection.  Mazor shall print and apply labels required by the Specification so that the labels remain legible and affixed during the customary conditions of processing, storage, handling, distribution, and use. Mazor shall inspect labels and labeling to ensure accuracy, including but not limited to the expiration date and control number, and shall document the release of labels and labeling in the DHR.

 

D.2.12.5.        Labeling Mix-Ups.  Mazor shall store labels and labeling in a way that prevents an incorrect label from being used with a Product. Mazor shall control labeling and packaging operations to prevent labeling mistakes, and shall document the label and labeling used for each production unit, Lot or batch in the DHR.

 

D.2.12.6.        Packaging.  The parties shall collaborate to ensure that the packaging and shipping containers for the Product(s) are designed and constructed to protect the Product(s) from alteration or damage during the customary conditions of processing, storage, handling, distribution and use in compliance with the Quality Management System requirements.

 

D.2.12.7.        Handling and Storage.  Mazor shall establish and maintain procedures for the handling, storage, shipment/distribution and installation of the Product(s) in compliance with the following.

 

		(i)	
Handling. Mazor shall have systems in place to ensure that mix-ups, damage, deterioration, contamination or other adverse effects do not occur during handling of the Product(s).

 

		(ii)	
Storage.  Mazor shall control storage areas to prevent mix-ups, damage, deterioration, contamination or other adverse effects pending shipment/distribution of the Product(s).

 

		(iii)	
Quarantined Product and Notification. Medtronic shall notify Mazor by telephone call and (with a follow up written notice (e.g., e-mail)) if quarantine of Product at Mazor is required.  Mazor shall hold all quarantined Product in a quarantined area (either electronically and/or physically) until authorized release by Medtronic.

 

D-8

D.3.         Production.  Mazor shall comply with the following regarding production of the Products.

 

D.3.1.      Process Control-Generally.  Mazor shall have systems in place to define and maintain the Manufacturing process and associated controls so that all Product(s) conform to their Specifications, including but not limited to:

 

D.3.1.1.          Documented and approved production processes, instructions, and methods that define and control the manner of production

 

D.3.1.2.          Monitoring and control of process parameters and Component and Product characteristics during production

 

D.3.1.3.          Compliance with specified reference standards or codes, if applicable

 

D.3.1.4.          Approval of processes and process equipment

 

D.3.1.5.          Criteria for workmanship which shall be expressed in documented standards or by means of identified and approved representative samples

 

D.3.2.      Process Monitoring and Control.

 

D.3.2.1.          Process Monitoring. Mazor shall monitor and control the Manufacturing process using the industry standard tools such as in-process inspection, Validation and statistical process control.

 

D.3.2.2.          Control Plan. Mazor shall collaborate with Medtronic to ensure a thorough understanding and identification of critical process steps, transfer function relationships, acceptable measurement capability and process capability of process input/outputs as to their impact on the critical features. Mazor shall collaborate with Medtronic to design an appropriate Control Plan that will ensure the long term stability and capability of the Manufacturing processes.  At the time of Qualification, Mazor shall incorporate the foregoing into a Control Plan which will be mutually agreed upon and approved by Medtronic. Mazor shall provide a measurement system analysis (e.g. gage repeatability and reproducibility, gage to part ratio), for each measurement process utilized in the Control Plan. These analyses and Control Plans will be filed with Mazor with a copy to Medtronic. On an ongoing basis, Mazor will monitor production and complete inspection of each Lot/batch per the Control Plan to ensure conformance. Mazor will include a Certificate of Conformance for each Lot/batch based on conformance to the Control Plan.

 

		(i)	
Statistical Techniques. Mazor shall, where appropriate, establish and maintain procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and Product characteristics in compliance with the Quality Management System requirements.

 

		(ii)	
In the event any of the Manufacturing process steps are outside of control limits or Manufacturing yields decline considerably, Mazor shall take appropriate corrective and preventive actions to rectify the situation and maintain documentation of the actions taken in compliance with Section B.2.8 (Document Controls and Changes).

 

D-9

D.3.2.3.          Contamination and Manufacturing Material Control. In addition to any requirements set forth in the Specifications, the Mazor shall establish and maintain procedures to prevent contamination of Product or Components that could adversely affect the Product quality.  Where a Manufacturing material could reasonably be considered to have an adverse effect on Product quality, the Mazor shall establish and maintain procedures for the use and removal of such Manufacturing material to ensure that it is removed or limited to an amount that does not affect the Product or Component’s quality. The removal or reduction of such Manufacturing material shall be documented.

 

D.3.2.4.          Certificate of Conformance.  Mazor shall provide to Medtronic a Certificate of Conformance/Analysis consistent with the Specifications for each lot/batch of Product shipped.

 

D.3.2.5.          Inspection, Measurement, and Test Equipment.  Mazor shall calibrate all inspection, measurement, and test equipment used in connection with any Product(s). Mazor shall notify Medtronic in writing of any out-of-tolerance equipment that may affect the testing or Manufacturing of any Product(s) or Component that is delivered to Medtronic. The written notification shall include identification of the affected Product(s) or Component.  Medtronic has the right to approve the disposition of the affected Product(s) or Component that was inspected, tested, or Manufactured with the out-of-tolerance equipment. Calibration for weights and measures shall be traceable to the National Institute of Standards and Technology.  The calibration schedule shall be posted on each individual piece of equipment.

 

D.3.3.      Approved Manufacturing Sites.  Mazor shall Manufacture the Product(s) only at Approved Manufacturing Sites for the applicable Products(s).

 

D.3.4.      All Product(s) delivered to, or for the benefit of, Medtronic by Mazor shall meet and be Manufactured in accordance with the Specifications and the requirements of this Quality Agreement.

 

D.4.         Design.

 

D.4.1.      Critical Feature.  Mazor shall identify all critical features and/or requirements of the Product(s) that require specific capability and control within the Mazor’s Manufacturing process. Mazor shall measure and record the identified Product features in an appropriate way.  Mazor shall Manufacture the Product according to all requirements on the drawing, Specifications, or other Mazor documents.

 

D.4.2.      Conflicts in Requirements.  If at any time a conflict arises between design requirements of this Quality Agreement and Product design documentation, Mazor shall notify Medtronic of the conflict.  Mazor shall resolve the conflict and communicate to Medtronic.

D-10

 

D.4.3.      Compliance with Design requirements.

 

D.4.3.1.          Design Controls. Mazor shall ensure that the Product(s) are designed and developed in compliance with the Design Control requirements of the Quality Management System. Mazor shall maintain the designs within its Quality System. Mazor shall ensure that the design of the Product(s) is correctly translated into production Specifications and shall not implement design changes unless Mazor receives updated Specifications and appropriate change authorization. These Design Control activities include:

 

		(i)	
Design and Development Planning. Mazor shall establish and maintain plans that describe or reference the Design and Development activities for the Product(s), that identify and describe the interfaces with the groups or activities that provide input to the Design and Development process for the Product(s), and that define responsibility for implementation, in compliance with Quality Management System Requirements. The plans shall be reviewed, updated and approved as the Design and Development evolves.

 

		(ii)	
Design Input. Mazor shall ensure that the design requirements for the Product(s) are appropriate and address the intended use of the Product(s) including the needs of the user and patient, in compliance with the Quality Management System Requirements.  Mazor has the sole authority to make design changes.

 

		(iii)	
Design Output. Mazor shall establish and maintain procedures for defining and documenting Design Outputs in a manner that allows adequate evaluation of the Product(s)’ conformance to Design Input requirements, in compliance with Quality Management System Requirements. The procedures shall reference acceptance criteria and shall ensure that the essential outputs are identified. Mazor shall document Design Output.

 

		(iv)	
Design Review.  Mazor shall establish and maintain procedures to ensure that formal documented reviews of the design results for the Product(s) are planned and conducted at appropriate stages of the Product’s Design and Development, in compliance with Quality Management System Requirements. The results of design reviews shall be documented in the Design History File (DHF).

 

		(v)	
Design Verification.  Mazor shall establish and maintain procedures for verifying the design of the Product(s), in compliance with Quality Management System Requirements. Design Verification shall confirm that the Design Output for the Product(s) meets the Design Input requirements and any other Mazor requirements.  Results of the verification shall be documented in the DHF.

 

		(vi)	
Design Validation.  Mazor shall establish and maintain procedures for Validating the design of the Product(s). Design Validation shall be performed under defined operating conditions on initial production units, Lots or batches, or their equivalents. Design Validation shall ensure that the Product(s) conforms to defined user needs and intended uses, and shall include testing of the Product(s) under actual or simulated use conditions. Results of Design Validation shall be documented in the DHF.

 

D-11

		(vii)	
Design Transfer.  Mazor shall establish and maintain procedures to ensure that the design of the Product(s) is correctly translated into production Specifications, in compliance with Quality Management System Requirements.

 

		(viii)	
Design Changes.  Mazor shall establish and maintain procedures for the identification, documentation, Validation (or where appropriate, verification), review and approval of design changes for the Product(s) before their implementation, in compliance with Quality Management System Requirements. Changes to the designs shall be governed by Mazor procedures.  Mazor shall notify Medtronic of design changes that may affect the safety, effectiveness, use, performance, sale, or distribution of the Product(s) and Mazor shall follow all appropriate change control procedures.

 

		(ix)	
Design History File.  Mazor shall maintain a DHF for the Product(s), which shall contain or reference the Records necessary to demonstrate that the design was developed in accordance with the design plan, the applicable Quality System requirements, and this Quality Agreement. Mazor shall own the Product’s DHF and it shall reside with Mazor for 3 years, after which time it may be transferred to a document retention site. Mazor shall have the ability to obtain access to the DHF within twenty-four (24) hours.

 

D.5.         Audits and Inspections.

 

D.5.1.      Medtronic Audits. Medtronic retains the right to audit Mazor’s Manufacturing and Quality Systems.  Medtronic and any third party consultant designated by Medtronic shall have reasonable access to observe and inspect Mazor’s facilities, Manufacturing and quality control processes, Manufacturing and quality control Records, Quality Systems, and all analytical and Manufacturing documentation related to the Products to ensure compliance to this Quality Agreement.  Such audits may include, without limitation, the following:

 

D.5.1.1.          Periodic Audits. Medtronic shall have the right to conduct at least one periodic audit each contract year.  Mazor shall provide Medtronic reasonable access to inspect, review and audit the site(s) where the Products are inspected, tested, handled, stored, distributed, designed and/or Manufactured, including access to the Products and all related design, product development and/or Manufacturing Records. Medtronic shall provide prior notice of inspection of not less than twenty (20) days, except when special circumstances warrant a shorter time, such as when patient safety is a concern, in which case the parties shall mutually agree on a time for prior notice.  Mazor shall not unreasonably reject proposed audit schedules. Medtronic reserves the right to audit Sub-tier suppliers under similar circumstances.  Mazor shall cooperate with and support such audits and shall use reasonable efforts to maintain contractual rights to such audits.

 

D-12

D.5.1.2.          For-Cause Audits.  For-cause audits shall be for the purpose of investigating a potential quality problem or significant complaint regarding a Product potentially attributable to Manufacturing or other operations at Mazor. If Medtronic believes a for-cause audit is needed, Medtronic shall notify Mazor of the request and reason for the for-cause audit. Mazor shall not unreasonably reject a request for a for-cause audit.  For-cause audits shall be scheduled as quickly as possible, taking into consideration the urgency of the request, but in no event later than ten (10) days from the request date.   Medtronic reserves the right to audit Sub-tier Suppliers under similar circumstances.   Mazor shall cooperate with and support such audits and shall use reasonable efforts to maintain contractual rights to such audits.

 

D.5.1.3.          Procedures While On Site. Medtronic’s employees and/or representatives including consultants who inspect Mazor facilities shall comply with all Mazor safety and GMP policies and procedures.  Medtronic assumes all liability for injuries to Medtronic’s employees and/or representatives including consultants to the extent arising from their negligent acts or omissions at Mazor facilities.

 

D.5.1.4.          Audit Closeout.  An exit meeting shall be held with representatives from Mazor and Medtronic to discuss audit findings and observations.  Medtronic shall provide a written report of all findings and observations to Mazor within thirty (30) days of the last day of the audit.  Within thirty (30) days of the audit report receipt, Mazor shall provide a written response to all findings that details Corrections and corrective action to be implemented.  Mazor shall follow up to ensure that all Corrections and corrective actions are implemented.

 

D.5.1.5.          Confidential Information.  All information or documents obtained by Medtronic in connection with an audit or inspection conducted pursuant to this Section D.5 shall be Confidential Information of Mazor as the term is defined in Section 26.1, and Medtronic agrees to abide by its obligations under Section 26 with respect to such Confidential Information.

 

D.5.2.      Internal Audits by Mazor.  Mazor shall conduct internal audits at least one time per year, to ensure compliance with its Quality System and this Quality Agreement.  Upon Medtronic’s request, Mazor shall provide Medtronic with the results and conclusions of the audits.

 

D.5.3.      Management of Sub-tier Suppliers.  Mazor is responsible for management of Mazor’s Sub-tier Suppliers based upon risk as determined per Mazor’s own internal procedures.  Medtronic shall have the option to provide input to risk assessment of Mazor’s Sub-tier Suppliers and shall require Mazor to escalate risk as applicable.  Medtronic and Mazor shall jointly determine which Sub-tier Supplier’s performance shall be reviewed during the Product and/or Process Performance reviews.

 

D-13

D.5.4.      Regulatory Audits and Inspections.  Mazor agrees the FDA and other Authorities shall have access to and the right to inspect or audit any pertinent Product(s) design, Manufacturing, or quality processes, and associated documentation or Records.

 

D.5.5.      Notification.

 

D.5.5.1.          Third Party Audits.  Mazor shall promptly notify Medtronic when an Authority inspection of its facilities (or an inspection by third parties in accordance with FDA regulations or inspection by regulatory agencies or by auditing bodies such as a notified body, test laboratories) relating to any Product(s) is expected and/or underway.  Notification shall include the name of the regulatory Authority or test lab/agency, dates, and the scope of activity.  Post audit notification shall include ongoing certification status, and the audit or inspection results, including any FDA Form 483 observations, ISO nonconformance, or test lab/agency variance notices.

 

D.5.5.2.          Identified Issues.  If issues are identified during any inspection or audit which are related to or will have a potential impact on the Product quality, performance or availability, Mazor shall notify Medtronic by email or phone within 24 hours of the event with written follow-up within three (3) Business Days.

 

D.5.5.3.          Regulatory Correspondence. Mazor shall promptly provide Medtronic with copies of all regulatory correspondence, including without limitation Form FDA 483s and FDA warning letters and any correspondence with the FDA or any other Authority related to processes, Components or equipment which are the same or similar to those used in the Manufacture of the Products.

 

D.5.6       Confidentiality.  Notwithstanding anything to the contrary in this Agreement, and except as compelled by law, in connection with any audit Mazor may withhold any document or information (i) that would cause a violation of any agreement to which Mazor is a party, (ii) that is subject to any attorney-client privilege; or (iii) that constitutes a trade secret.

D.6.         Complaint Handling.

 

D.6.1.      Cooperation. Each Party shall cooperate fully with the other Party in dealing with customer and third party complaints concerning the Product (s) and shall take such action to promptly resolve such complaints as may be reasonably requested by the other Party.

 

D.6.2.      Mazor Obligations. Without limiting the generality of the foregoing, Mazor shall:

 

D.6.2.1.          Give notice to Medtronic as soon as reasonably practicable if Mazor becomes aware of a trend in complaints related to the Product(s).

 

D.6.2.2.          Maintain a written Record of all customer and third-party complaints received by Mazor that relate to the Product(s), whether received orally or in writing.

 

D.6.2.3.          Establish a tracking system for all Product(s) so as to permit successful tracking in the event of a Recall.

 

D-14

D.6.2.4.          Maintain complaint Records and files in accordance with Quality System requirements.

 

D.6.3.      Mazor Authority.  Mazor shall have the sole authority to correspond with all applicable regulatory authorities with respect to complaints about the Product(s).

 

D.7.         Medical Device Reporting.  Mazor is responsible for complying with all applicable FDA and foreign regulatory requirements pertaining to the reporting of adverse device events, including FDA’s Medical Device Reporting requirements, codified at 21 C.F.R Part 803. If

 

D.7.1.      Medtronic Obligations.  Without limiting the generality of the foregoing, Medtronic shall:

 

D.7.1.1.          Maintain a Record of all customer and third-party complaints and reports of adverse events related to the Product(s), whether received orally or in writing.

 

D.7.1.2.          Medtronic will report to Mazor within two (2) business days when it suspects that one of Mazor’s devices may have caused or contributed to a death or serious injury.  Mazor will assess the event and provide Medtronic with its conclusions and justifications within the required regulatory timeframes.  If Mazor and Medtronic agree that an adverse device event is reportable, then each company shall follow its own notification requirements as a manufacturer and distributor/importer, respectively, as required by law or regulation.  If Medtronic disagrees with Mazor, and believes that an adverse device event is reportable, then Medtronic will inform Mazor of its opinion in advance and follow Medtronic’s notification requirements as a distributor/importer as required by law or regulation.

 

D.7.1.3.          Establish a tracking system for all Product(s) so as to permit successful tracking in the event of a Recall; and

 

D.7.1.4.          Maintain Records and files of the complaints and reported adverse events.

D.7.2.      Mazor Authority. Mazor shall have the authority to correspond with all applicable regulatory authorities with respect to complaints about the Product(s).

 

D.8.         Device Recalls.

 

D.8.1.      Complaints. If the either Party becomes aware of any defect or problem with respect to any Product that could reasonably require a Recall of the Product, that Party shall notify the other Party within two (2) Business Days after becoming aware of the issue.  If such issue may have caused or contributed to death or serious injury, either Party shall promptly notify the other Party, and in any event no later than twenty four (24) hours after becoming aware of the issue.

 

D.8.2.      Notification.  If either Party in good faith determines that a Recall or other action involving a Product(s) should be considered, such Party shall immediately notify the other Party (and in the event that Medtronic is the notifying Party, such notification to Mazor shall be prior to any notification to any Authority to the extent permitted by Applicable Law) and shall advise such other Party of the reasons underlying its determination.

 

D-15

D.8.3.      Recall Determination.  Mazor has the right, in its sole discretion, to determine whether any action such as a Recall or other action should be undertaken. In the event of a Recall, the Parties shall cooperate in addressing Recall activities.

 

D.8.4.      Credit.  Mazor shall be responsible for either replacing or issuing a credit for any Product that is subject to any mandatory or voluntary Recall to the extent such Recall is caused by the failure of Mazor: a) to comply with any requirement or directive of a regulatory body; or b) to meet any Mazor specification.

 

D.8.5.      Analysis.  Product returned related to Recall shall be analyzed by Mazor.

 

D.9.         Regulatory Approval of Product Modifications.  In those countries where Mazor holds the regulatory approval certificate in their name, Mazor shall be responsible for making the determination as to whether proposed Product modifications require regulatory approval prior to implementation.  Mazor shall be responsible for filing and obtaining any required approvals, clearances and/or supplements and Medtronic will provide reasonable assistance to Mazor.  In those countries where Medtronic holds the regulatory approval certificate in their name for a Product, Medtronic shall be responsible for making the determination as to whether proposed Product modifications require regulatory approval prior to implementation.  Medtronic shall be responsible for filing and obtaining any required approvals, clearances and/or supplements and, subject to any exceptions in Section 20.2 of the Agreement, Mazor will provide reasonable assistance to Medtronic.

 

D.9.1.      Change Management and Notification.  When a change is made to a Product design, its manufacturing, inspection, labeling, packaging, or sterilization, the changes should be reviewed for regulatory impact in any geography where it is approved or has a pending submission by the Mazor. If such changes require notification of Authorities, Mazor will notify Medtronic at the time of the notification determination or submission.  In addition, upon the regulatory agency’s approval of the change, the Mazor shall notify Medtronic and provide Medtronic with documentation submitted to the Authority in connection with changes to the Product.  In the event changes as outlined in this paragraph are made by Mazor, Mazor shall not ship revised Product to Medtronic without Medtronic’s prior written approval.

 

D.10.      Registration and Listing.  If applicable, each Party shall be responsible for compliance with U.S. FDA’s applicable establishment registration and medical device listing requirements set forth in 21 CFR Section 807.40. Mazor shall provide Medtronic with confirmation of FDA establishment registration upon request by Medtronic. Mazor shall be responsible for listing the Products(s) with U.S. FDA in accordance with 21 CFR Section 807.40.

 

D.11.      Compliance History.  Mazor shall provide Medtronic with a review of Mazor’s regulatory compliance history, which, in the U.S. shall include, but not be limited to: (i) any Form FDA 483 List of Inspectional Observations from FDA inspections conducted within the last five (5) years and any related correspondence between the Mazor and FDA; (ii) any FDA warning letters and related correspondence between the Mazor and FDA within the last five (5) years; and (iii) all reports and/or findings from any third party audits, including, but not limited to audits conducted by a Notified Body, and related correspondence between the Mazor and the third party auditor, within the last five (5) years.

 

D-16

D.12.      Remedies.

 

D.12.1.    In the event that any Product has been rejected in accordance with this Quality Agreement and Medtronic has notified Mazor, Mazor shall replace such Product free of charge and Mazor shall cover expenses (including freight and customs clearance, if any) incurred by Medtronic in connection with (a) shipment of replacement Product to the same location and (b) shipment of the Nonconforming Product back to Mazor (if so requested by Mazor). In the event of a rejection of defective Product, Mazor shall ship replacement Product as soon as practical, but in any event within thirty (30) days, or a longer time period if agreed upon by the parties, of its receipt of a proper rejection notice from Medtronic.

 

D.12.2.    In the event that a Recall is caused by Product that is nonconforming under this Quality Agreement or does not meet the Specifications being shipped to Medtronic, Mazor shall be solely responsible for all costs and expenses incurred by Medtronic in connection with replacing or reworking the Product subject to such Recall.

D.13.      Product and Process Reviews.  Medtronic and Mazor shall respectively provide and review once each year, at a minimum, the information set out in the table below. Records of these reviews shall be considered a Medtronic quality Record.

 

	

Metric / Information

	
Medtronic

Provides

	
Mazor

Provides

	
Product performance results

	
X

	
X

	
Field Action Update

	
X

	
X

	
Product CAPA

	 	
X

	
Process CAPA (including supply chain)

	 	
X

	
Concession review and associated CAPA

	 	
X

	
Process first pass yield & defect pareto analysis

	 	
X

	
Source & receiving inspection results

	
X

	
X

	
Quality System certification / regulated audit status:

          External audits

          Nonconformities

          Status of QS certifications

          Test lab /agency status (if applicable)

	 	
X

	
Design change control update

	 	
X

	
Process change control update

	 	
X

	
Business process Specification maintenance

	
X

	 
	
Quality Agreement maintenance

	
X

	
X

	
Control Plan status

	 	
X

	
Results of Mazor audit by Medtronic (if applicable)

	
X

	 
	
Sub-tier Supplier performance (as applicable)

	 	
X

D-17

D.14.          Record Production and Retention.

 

D.14.1.          Creation and Maintenance. Each Party shall create and maintain Records for the activities for which they are responsible under this Quality Agreement in compliance with the Quality Management System requirements.

 

D.14.2.          Quality System Record. Mazor shall maintain a Quality System Record for Product(s)  in compliance with the Quality Management System requirements.

 

D.14.3.          Regulatory Compliance. The parties shall comply with any regulatory Record keeping requirements that apply to the performance of such Party’s obligations under this Quality Agreement. If applicable, Mazor shall maintain electronic records and electronic signatures according to the requirements in to 21 CFR Part 11.

 

D.14.4.          Ownership. All such Records and other documents required to be maintained pursuant to this Quality Agreement and provided by Medtronic shall be the sole property of Medtronic.

 

D.14.5.          Storage. Records and other documents shall be maintained and readily retrievable to provide reasonable ease of access for review. Records and other documents shall be legible and stored to minimize deterioration and prevent loss.

 

D.14.6.          Location of Records/Record Inspection.  Medtronic approvals of Mazor documents (process changes, out of calibration dispositions, or other Quality System Records) shall be an input to the Mazor’s Quality System. Records and other documents required to be maintained pursuant to this Quality Agreement shall be available at reasonable times for inspection, examination and copying by or on behalf of Medtronic, or for inspection by third parties, including FDA, for so long as any of them are in Mazor’s possession.

 

D.14.7.          Copies.  Upon Medtronic’s request, Mazor shall promptly provide Medtronic with copies of non-proprietary portions of Records and other documents required to be maintained pursuant to this Quality Agreement.

 

D.14.8.          Retention.  Mazor shall keep Record for 5 years from date of Record creation; thereafter, Mazor shall transfer custody of the Records to Medtronic. At any time upon written request, or termination of this Quality Agreement, Mazor shall return all Records relating to design master records, design history records and design history files for any Products to Medtronic.

 

D-18

EXHIBIT E

STATEMENT OF WORK #1

[THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]

 

E-1Exhibit 4.18

 

Amendment No. 1 to Mazor Robotics Ltd. 2011 Share Option Plan

 

THIS AMENDMENT NO. 1 to the Mazor Robotics Ltd. (the “Company”) 2011 Share Option Plan (the “Amendment” and the “Plan”, respectively) amends the Plan as set forth below effective as of the date approved by the Company’s Board of Directors (the “Board”). All capitalized terms not specifically defined in this Amendment shall have the meanings provided to them in the Plan.

 

WHEREAS, the Company, a corporation organized under the laws of the state of Israel, originally adopted the Plan on May 30, 2011; and

 

WHEREAS, the Board may, at any time, amend the Plan provided that such amendment does not impair the rights of the Grantees under an Award Agreement; and

 

WHEREAS, the Board has determined that it is advantageous to the Grantees to amend the Plan to enable the Company to issue Restricted Share Units (as defined below) to the Grantees.

 

NOW, THEREFORE, the Plan is hereby amended as follows:

 

	1.	
The title of the Plan is hereby amended to read as follows:

 

“Mazor Robotics Ltd. 2011 Share Option and Equity Incentive Plan”.

 

	2.	
The first sentence of the Plan is hereby amended in its entirety to read as follows:

 

“This plan, as amended from time to time, shall be known as the Mazor Robotics Ltd. 2011 Share Option and Equity Incentive Plan (the “Plan”).

 

	3.	
All references to the terms “Option(s)” and “Stock Options” shall be replaced by the terms “Award(s)” save for Sections 9.2, 9.3 and 12 of the Plan, which shall apply to Options only.  All references to an exercise of an Award shall, as the context requires, also include the settlement of a Restricted Share Unit Award.

 

	4.	
SECTION 1 – PURPOSES OF THE PLAN

 

In the final sentence of Section 1, the words “opportunities to purchase shares” shall be replaced with the words “opportunities to purchase or acquire shares.”

 

	5.	
SECTION 2 - DEFINITIONS

 

		5.1	
The definition of “Adoption Date” in Section 2.2 of the Plan is hereby amended in its entirety to read as follows:

 

“Adoption Date means the date on which the Board adopted this Plan or any amendment thereto”

 

		5.2	
Section 2 of the Plan shall be amended by renumbering Sections 2.3 through 2.33 as Sections 2.4 through 2.34, and adding the following definition as new Section 2.3:

 

“ADS means American Depository Share.”

 

		5.3	
The definition of “Applicable Laws” in Section 2.4 of the Plan is hereby amended in its entirety to read as follows:

 

“Applicable Laws means the requirements relating to the adoption of and/or the administration of share option plans and equity incentive plans under the relevant laws and regulations of the State of Israel, any share exchange or quotation system on which the Shares may be listed or quoted and the applicable laws of any other country or jurisdiction where Awards are granted under the Plan, as well as the Articles of Association of the Company.”

 

 

		5.4	
The definition of “Award” in Section 2.6 of the Plan is hereby amended in its entirety to read as follows:

 

“Award shall mean any Option, or Restricted Share Unit Award, granted to a Grantee under the Plan.”

 

		5.5	
Section 2 of the Plan shall be amended by renumbering Sections 2.20 through 2.34 as Sections 2.21 through 2.35, and adding the following definition as new Section 2.20:

 

		“2.19	
Fair Market Value means the closing transaction price (or, at the discretion of the Committee, the real time price) of a Share or an ADS (as the case may be), as reported on the Tel Aviv Stock Exchange or Nasdaq, as relevant, on the date as of which such value is being determined; provided, however, that if Fair Market Value for any date cannot be so determined, Fair Market Value shall be determined by the Committee by whatever means or method as the Committee, in the good faith exercise of its discretion, shall at such time deem appropriate.”

 

		5.6	
Section 2 of the Plan shall be amended by renumbering Sections 2.25 through 2.35 as Sections 2.26 through 2.36, and adding the following definition as new Section 2.25:

 

		“2.25	
Option means an award of a stock option under this Plan.”

 

		5.7	
Section 2 of the Plan shall be amended by renumbering Sections 2.27 through 2.36 as Sections 2.29 through 2.38, and adding the following definitions as new Sections 2.27 and 2.28:

 

		“2.27	
Performance Measures means the criteria and objectives, established by the Committee, which shall be satisfied or met during the applicable Performance Period as a condition to the entitlement and/or vesting of an Award.

 

		  2.28	
Performance Period means any period designated by the Committee during which the Performance Measures applicable to an Award shall be measured.”

 

		5.8	
The definition of “Plan” in Section 2.29 of the Plan is hereby amended in its entirety to read as follows:

 

“Plan means this Mazor Robotics Ltd. 2011 Share Option and Equity Incentive Plan, as amended and in effect from time to time.”

 

		5.9	
Section 2 of the Plan shall be amended by renumbering Sections 2.32 through 2.39 as Sections 2.35 through 2.41, and adding the following definitions as new Sections 2.32 through 2.34:

 

		“2.32	
Restricted Share Unit means a right to receive one Share or, in lieu thereof, the Fair Market Value of such Share in cash, which shall be contingent upon the expiration of a specified Restriction Period and/or contingent upon the attainment of specified Performance Measures within a specified Performance Period.”

 

- 2 -

 

		 2.33	
Restricted Share Unit Award means an award of Restricted Share Units under this Plan.

 

		 2.34	
Restriction Period means any period designated by the Committee, in its absolute discretion, the completion of which shall result in the vesting of the applicable Restricted Share Unit Award.  The Committee shall have the authority to accelerate the vesting of any outstanding Restricted Share Unit Award at such time and under such circumstances as it, in its sole discretion, deems appropriate.”

 

		5.10	
The reference to “Section 8.4” in Section 2.41 of the Plan (“Vesting Schedule” shall be revised to be a reference to “Section 8.1.4.”

 

	6.	
SECTION 3 - TYPES OF AWARDS

 

Section 3 of the Plan is hereby amended in its entirety to read as follows:

 

“The Plan is intended to enable the Company to issue Awards subject to Applicable Law  and to Section 4, including without limitation (i) Awards without a trustee pursuant and subject to the provisions of Section 102 of the Israeli Income Tax Ordinance (New Version) 1961 (the “Ordinance”), as amended and any regulations, rules, orders or procedures promulgated there under including tax rules (Preferential Tax Treatment regarding Issuance of Shares to Employees), 2003 (“Section 102”) (such awards, “Non Trustee 102 Awards”); (ii) Awards allocated to a Trustee under the capital gains track pursuant and subject to the provisions of Section 102 of the Ordinance (such awards, “102 Capital Gain Awards”); (iii) Awards allocated to a Trustee under the ordinary income track pursuant and subject to the provisions of Section 102 of the Ordinance (such awards, “102 Ordinary Income Awards”); and (iv) Awards pursuant to Section 3(i) of the Ordinance (“3(i) Awards”) (all Non-Trustee 102 Awards, 102 Capital Gain Awards, 102 Ordinary Income Awards, 3(i) Awards each an “Award”, and collectively, the “Awards”).  Apart from issuance under the relevant tax regimes in the State of Israel, the Plan contemplates issuances to Grantees in other jurisdictions with respect to which the Administrator is empowered to make the requisite adjustments in the Plan and set forth the relevant conditions in the Company’s agreement with the Grantee in order to comply with the requirements of the tax regimes in said jurisdictions.

 

The Plan contemplates the issuance of Awards by the Company, both as a private company and as a publicly traded company.”

 

	7.	
SECTION 5 - AUTHORIZED AWARDS

 

In Section 5.5 of the Plan the words “share option” in the last sentence shall be replaced with the words “option or share plans.”

 

	8.	
SECTION 6 – ADMINISTRATION

 

In Section 6.2.7, the words “minimum statutory withholding amount” shall be replaced with the words “withholding amount.”

 

	9.	
SECTION 8 - AWARD AGREEMENTS

 

Section 8.1.3 of the Plan is hereby amended in its entirety to read as follows:

 

		“8.1.3	
Exercise Price. If applicable, each Award Agreement shall state the Exercise Price of the Award Shares to which the Award relates. The Exercise Price shall be subject to adjustment as provided in Section 16 hereof.”

 

- 3 -

 

	10.	
SECTION 9 - TERM OF THE PLAN

 

		10.1	
Section 9.2 of the Plan is hereby amended in its entirety to read as follows:

 

		“9.2	
Exercise of Options. The Options granted will be exercisable into Shares of the Company according to the Vesting Schedule set forth in the Award Agreement or in this Plan.”

 

		10.2	
The first paragraph of Section 9.3 of the Plan is hereby amended in its entirety to read as follows:

 

		“9.3	
Exercise Price. If applicable, the Exercise Price of the Options subject to each Award Agreement shall be determined by the Administrator, provided however, that such Exercise Price shall not be less than the par value of the share into which such Option is exercisable. The Committee may, at its sole discretion, consider allowing net exercise, or any other exercise method, subject to the provisions of applicable law. If, as of the date of exercise of an Award the Company is then permitting net exercises, the Grantee will be able to engage in a “same-day sale” cashless brokered exercise program, involving one or more brokers, through such a program that complies with the applicable laws and that ensures prompt delivery to the Company of the amount required to pay the Exercise Price and any tax”

 

	11.	
SECTION 11 – METHOD OF EXERCISE

 

		11.1	
The title of Section 11 of the Plan is hereby amended in its entirety to read as follows:

 

		“11.	
Terms of the Awards”

 

		11.2	
Section 11.1(ii) of the Plan is hereby amended in its entirety to read as follows:

 

		“(ii)	
full payment for the Award Shares with respect to which the Award is exercised as set forth in Section 12.1 below, or, in the event of a net exercise (as described in Section 9.2 above), the surrender of the relevant portion of the Shares, at the Company’s principal office.

 

		11.3	
Section 11 of the Plan shall be amended by adding the following as new Section 11.4:

 

		“11.4	
Terms of Restricted Share Unit Awards.

 

Restricted Share Unit Awards shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of this Plan, as the Committee shall deem advisable.

 

		11.4.1	
Number of Shares and Other Terms. The number of Shares subject to a Restricted Share Unit Award and the Restriction Period, Performance Period (if any) and Performance Measures (if any) shall be determined by the Committee.

 

		11.4.2	
Vesting and Forfeiture. The Award Agreement relating to a Restricted Share Unit Award shall provide, in the manner determined by the Committee, in its discretion and subject to the provisions of this Plan:

 

		(i)	
For the vesting of such Restricted Share Unit Award (a) if the Grantee of such Award remains continuously in the employment of the Company and its Subsidiaries during the specified Restriction Period and/or (b) if specified Performance Measures (if any) are satisfied or met during a specified Performance Period; and

 

- 4 -

 

		(ii)	
For the forfeiture of the Restricted Share Unit Award (a) if the Grantee of such Award does not remain continuously in the employment of the Company and its Subsidiaries during the specified Restriction Period and/or (b) if specified Performance Measures (if any) are not satisfied or met during a specified Performance Period.

 

		11.4.3	
Settlement of Vested Restricted Share Unit Awards.

 

Prior to the settlement of a Restricted Share Unit Award, the Grantee of such Award shall have no rights as a shareholder of the Company with respect to the Shares subject to such Award.

 

For the avoidance of doubt, Shares issued pursuant to the settlement of a Restricted Share Unit Award shall be “Award Shares” for all purposes under the Plan.

 

		11.4.4	
Delivery. A delivery of Shares in settlement of a Restricted Share Unit Award that vests based on a specified Restriction Period, Performance Measure(s) or any combination thereof shall occur as soon as administratively practicable following vesting, but in no event later than the fifteenth day of the third month following the close of the year in which the later of the Restriction Period or the Performance Period ends.

 

		11.4.5	
Dividend Equivalents. With respect to each Restricted Share Unit Award, the Committee, at its sole discretion, may grant a dividend equivalent unit to any Grantee upon such terms and conditions as it may establish.  Each dividend equivalent unit will entitle the Grantee, at the time of the settlement of the Award, to an additional payment equal to the dividends the Grantee would have received if the Grantee had been the actual record owner of the underlying Shares on each dividend record date prior to settlement.  The dividend equivalent unit may be settled in Shares or cash or a combination thereof.”

 

	12.	
Except to the extent amended hereby, the terms and provisions of the Plan shall remain in full force and effect.

 

This Amendment has been adopted by the Board of Directors of the Company as of January 1, 2018.

 

Chairman of the Board of Directors:

 

/s/ Jonathan Adereth

 

Jonathan Adereth.

 

- 5 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]